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Abstract
Opportunities and limitations of multileaf collimator based intensity modulated
proton therapy
The vast majority of proton therapy institutes employ passive scattering beamlines. Treatments
are delivered by means of laterally and distally conformed homogeneous dose distributions for
each beam direction by utilizing spread-out Bragg peaks and custom milled hardware. Most
newly built proton facilities rely upon scanned proton beams to provide intensity modulated
therapy (IMPT), improvements in treatment planning and delivery workflow. This thesis
investigates the benefits of IMPT in fixed proton therapy beamlines and describes aspects of
multileaf collimator (MLC) based IMPT delivery. We show that IMPT has the potential to
increase the range of applications for fixed proton therapy beamlines. A method for sequencing
intensity modulated treatment plans into a set of segments is presented and evaluated based on
results obtained for a set of clinical situations. The resulting numbers of segments made delivery
technically and logistically feasible. Neutron dose was found acceptable given a well optimized
beamline. The dosimetric properties of one specific multileaf collimator were investigated
experimentally and compared to custom milled apertures. Small differences were found, but
those are clinically insignificant in the vast majority of clinical cases. Finally, an extensive
set of measurements for accurate determination of the peak dose as a function of field size is
described.
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Zusammenfassung
Potenzial und Limitierungen von MLC basierter IMPT Anwendung
Die Mehrheit existierender Protonentherapiezentren nutzt passiv streuende Protonenstrahle-
nanlagen. Patientenbehandlungen basieren auf lateral und distal konformierten homogenen
Dosisverteilungen, die von jedem einzelnen Strahl durch spread-out Bragg Peaks und individu-
ell gefertigte Kollimatoren und Kompensatoren geliefert werden. Die Mehrheit der im Bau
befindlichen Protonenzentren installiert Scanning Systeme auf Grund ihrer Fa¨higkeit zu inten-
sita¨tsmodulierter Protonentherapie (IMPT), sowie ihrer Vorteile im Bezug auf Vereinfachung
der Arbeitsabla¨ufe der Bestrahlungsplanung und -lieferung. Das Potenzial von IMPT speziell
im Bezug auf fixe Protonenstrahlen liegt in einer Erweiterung derer Anwendungsmo¨glichkeiten.
Diese Arbeit schla¨gt Multileafkollimatoren (MLCs) fu¨r die nachtra¨gliche Ausru¨stung existieren-
der passiv streuender Protonenstrahlanlagen zur Anwendung fu¨r IMPT vor. Es wird eine
Methode zur Sequenzierung von Dosisverteilungen in Serien von Einzelsegmenten vorgestellt
und anhand einer Gruppe klinischer Anwendungen evaluiert. Basierend auf der resultierenden
Anzahl von Segmenten pro Strahlrichtung wa¨re die praktische Umsetzung der vorgeschla-
genen Methode technisch und logistisch mo¨glich. Die Neutronendosis war akzeptabel mit
der Bedingung einer optimal abgestimmten Protonenstrahlanlage. Die dosimetrischen Eigen-
schaften eines speziellen MLCs wurden untersucht und mit den u¨blich benutzten individuell
gefertigten Messingaperturen verglichen. Die gefunden Unterschiede sind klein und in der
Mehrheit klinischer Anwendungen vernachsla¨ssigbar. Abschliessend wird die Relation zwischen
Strahlmaximumsdosis und Feldgro¨sse als wichtiger Teil der MLC basierten IMPT Dosislieferung
ero¨rtert.
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Preface
This PhD thesis was carried out at the Massachusetts General Hospital (MGH)
between November 2006 and December 2010. The work describes benefits of IMPT for
fixed passive scattering beamlines and an approach for MLC based IMPT delivery.
The work presented in Chapter 2.1 has in parts been funded by an MGH grant and will
be submitted for publication soon. Publications covering the contents of Chapters 3.1 and
3.2 can be found in [1] and [2], respectively. The topic of Chapter 3.2 has been addressed
in [3] but has since been much expanded with an improved methodology. Parts of single
chapters were presented at international conferences [4] [5] [6] [7]. The contribution for
PTCOG 48 in Heidelberg [7] was awarded the PTCOG prize for best Physics poster.
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Chapter 1
Introduction to proton therapy
1.1 External Beam Radiotherapy
Application of radiation in medicine is broadly categorized into diagnostics and therapy.
In modern radiotherapy, both are relevant.
The basis of external beam radiotherapy treatment planning are in most cases
computed tomography images of the patient acquired in treatment position. A radiation
oncologist delineates the target as well as organs at risk on each slice of this image
set, and prescribes desired dose levels. Oftentimes additional information from other
imaging modalities, such as magnetic resonance and positron emission tomography, is of
importance for the definition of visible disease (gross tumor volume, GTV). The majority
of indications require expansion of the GTV into a clinical target volume (CTV) to
include microscopic disease not visualized on images. To account for uncertainties in
positioning of the patient most treatment protocols demand another expansion of the
CTV into a planning target volume, PTV [8] [9].
With target and avoidance structures defined, a treatment planner sets up the
geometry, for example number of beams and their directions, and dosimetry, for example
the weight of each beam, of a treatment plan. Dose is calculated based on electron
densities of the tissue as derived from the CT. Treatment is typically delivered by compact
medical accelerators using 4 - 25 MV photon beams. Depending on site and clinical
indication patients receive doses in a wide variety of fractionation schemes - from more
than 20 Gy in a single treatment session up to 80 Gy in small daily fractions of 2 Gy.
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Figure 1.1: Front view of the mini-multileaf collimator manufactured by Integra Radionics.
Leaves can take individual positions and thus shape arbitrary aperture outlines.
The most common treatment techniques in high energy photon radiotherapy nowadays
are 3D conformal (3D CRT) and intensity modulated radiotherapy (IMRT, [10] [11]). In
3D-CRT dose is delivered typically using three to five beam directions. The intensity
along the beam’s cross section is either constant, or - with aid of additional hardware
such as steel or tungsten wedges - sloped in one direction. The beam aperture is modified
on a beam-by-beam basis according to the projected shape of the target by custom made
blocks or multileaf collimators (MLC, Figure 1.1). The treatment planner chooses wedges,
beam shapes and angles in a manual iterative process until the desired dose to target
and critical structures is achieved.
The advent of multileaf collimators enabled the routine implementation of more
complex intensity modulation than can be provided by wedges. The basic idea of
intensity modulated radiotherapy (IMRT) is the two-dimensional modulation of the
intensity of a beam across its profile in both directions through the delivery of multiple
aperture shapes (segments) per beam (i.e. step and shoot IMRT), or even by continuous
variation of leaf positions (dynamic IMRT) [12]. Latest developments in the field include
rotational IMRT - continuous variation of leaf positions while rotating the beam around
the patient. In the following, we restrict ourselves to an overview of the process for
step-and-shoot IMRT delivered with a multileaf collimator.
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1.2 Intensity Modulated Radiotherapy
The treatment planning process in IMRT is inverted compared to 3D conformal techniques:
the user sets constraints for the dose distribution, such as minimum dose to the target and
maximum dose for organs at risk (OAR), and starts calculation. During computation each
beam is split up into elements, beamlets. The dose contribution of each beamlet to each
point in the patient is determined first. The problem of deriving the respective beamlet
intensities to achieve a result close to the desired dose distribution in the patient is solved
in an automated optimization process. This entire process, however, still requires some
manual iteration and an experienced user to obtain satisfactory results. One method of
minimizing user intervention is given with multi–critera optimization [13] [14] (MCO).
The treatment planning system calculates a library of treatment plans that all fulfill
the desired hard constraints. The user additionally specifies objectives, as for example
‘maximize the mean dose to the target’ and ‘minimize mean dose’ to OAR X, and can
navigate between the various plans on the pareto-surface via a graphical user interface.
For the final dose calculation the 2D intensity maps - the outcome of the optimization
- still have to be segmented, i.e. translated into deliverable sequences of aperture shapes.
Optimal properties for a ‘sequencer’ are to minimize the number of segments and monitor
units at the same time.
For an accurate representation of all scatter effects, dose has to be recalculated after
segmentation. The resulting dose distribution may be degraded enough to necessitate
repetition of the optimization process with altered constraints.
To eliminate this last step, as well as to reduce complexity of intensity maps, and
thereby reduction of number of monitor units and segments, direct aperture optimization
has been suggested [15] [16] [17]. The reader is referred to Khan [18] for more detail on
radiotherapy.
1.3 Proton Radiotherapy
While external beam therapy with photons is a widely available treatment technique in
thousands of centers worldwide, there are less than 35 operational proton therapy centers.
This number is, however, currently experiencing a steep increase. The great promise of
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Figure 1.2: Left: 1949. The first accelerator at the Harvard cyclotron laboratory that
was used for patient treatments (From R. Wilson’s library). Right: Modern
proton gantry (IBA, Belgium) with extended imaging panels for patient setup
verification. Currently existing proton therapy facilities feature one particle
accelerator, cyclotron or synchrotron, delivering beams to multiple treatment
rooms. Total weight of the gantry is approximately 100 metric tons. Facilities
have a large footprint in both required space and cost.
proton therapy is the reduction of integral dose compared to photons. The obstacle, on
the other hand, is the increased technical challenge and thereby cost.
Photons and protons undergo fundamentally different interaction processes when
traversing through media. The depth dose curves for photons is mainly determined by
the exponential decrease of primary fluence through Compton and coherent scattering,
photo-effect as well as pair production at higher energies. Since photons do not carry
electrical charge, they are termed indirectly ionizing radiation - the actual dose is delivered
by electrons that were freed by the photons. It takes some distance for longitudinal
charged particle equilibrium to be established. This gives rise to a build-up region of the
depth dose curve. Protons are directly ionizing. Their main mode of interaction with the
medium is collision with electrons, in which the latter are freed from their atoms and
receive kinetic energy. Most of those secondary particles have very short ranges, but some
receive enough energy to ionize matter themselves (delta rays). Inelastic electromagnetic
interactions with nuclei are possible as well, but of minor importance for energies as high
as considered here.
The energy loss per unit length due to electromagnetic interactions with electrons
in a material has been described for the first time by Bethe and Bloch in their 1930
publication [19]. It was later discussed and modified in various publications [20] [21] [22]
[23]. This quantity is called stopping power, and is usually normalized to the density
of the considered medium to yield mass stopping power. Stopping power is roughly
Introduction to proton therapy 11
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Figure 1.3: Left: Discoloration of transparent plastic block (dimensions: ≈ 20 x 20 x 5 cm3)
by a proton Bragg Peak. Made by Ethan Cascio in a 45 minute irradiation with
1015 170 MeV protons, depositing approximately 500 kGy in the entrance region.
Finite range and increased scatter in the peak are well visible. Formation of
color centers in solid material is a complex process [29]. In the region with the
highest dose color actually becomes lighter in our sample. We attribute this to
annihilation of color centers due to insufficient heat dissipation because of the
high dose rate during irradiation. Right: Monte Carlo simulated proton depth
dose in water.
proportional to the inverse of the square of the proton’s speed. This gives rise to the
‘Bragg Peak’ (see Figure 1.3), a proton’s most valuable property for therapy purposes.
The pathlength of a proton in a medium is obtained by integrating the inverse mass
stopping power over energy. Since the energy loss per proton electron collision is of
statistical nature, the Bragg Peak of a proton beam always has a certain width. This
property is called range straggling. In clinical practice a proton beam is usually described
by its range, rather than energy. Standard tables are in use for the conversion [20] [21].
The shape of the lateral dose distribution is determined by multiple coulomb scattering
(MCS) the elastic electromagnetic interaction of a proton with a nucleus, in which the
proton is scattered at an angle. The magnitude of the mean scattering angle is determined
by the atomic number of the material, and energy of the proton. A particle therefore
never passes through a medium in a straight line, but rather takes a random zigzag
course. The mean projected range can be calculated by integrating over the product
of inverse mass stopping power and cosine of the average scattering angle. The mean
scattering angle was described by Moliere and later approximated by Highland with
reasonable accuracy [24] [25] [26] [27]. Safai et al [28] have reported on the width of the
lateral dose fall-off as a function of depth and energy for collimated and uncollimated
proton therapy beams, shown in Figure 1.4.
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Figure 1.4: Lateral penumbra as a function of depth and energy for collimated and uncolli-
mated proton beams. From Safai et al [28].
A small fraction of the deposited dose is due to nuclear interactions, in which secondary
particles are generated. This latter effect also gives rise to a small buildup of dose in
the entrance region to establish longitudinal equilibrium of secondaries created in those
nuclear interactions. Some of the secondary particles have long ranges - neutrons are
contributing to the dose to the patient distant from the targeted site.
There are two general methods to manipulate proton beams for therapy purposes:
passive scattering and beam scanning. The common goal is to deliver the prescription
dose uniformly throughout a clinical target, as conformal as possible. Passive scattering,
as the name gives away, exploits the scattering properties of protons, see for example
[30]. An incoming pencil beam, about 2 cm in diameter, hits a series of scatterers and
absorbers in order to shape the lateral and longitudinal form of the dose distribution.
A useful diameter of about 25 cm homogenous dose can be produced by a combination
of scatterers of various materials and shapes. Spreading of the high dose region in
depth is achieved by energy modulation: peaks of several energies are superimposed with
appropriate weights to obtain a spread-out Bragg Peak (SOBP). Additional hardware
is necessary for lateral and distal conformity, shown in Figure 1.5. These pieces are
custom milled for every beam direction used for a patient”s treatment. Alternatively
to custom milled apertures, multileaf collimators may be employed for 3D-conformal
proton therapy [31]. Similar to IMRT it may be possible to use multileaf collimators for
intensity modulation in proton therapy.
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Figure 1.5: In passive scattered proton therapy custom made hardware is necessary for
conformation of each treatment field. Left: Brass aperture for lateral conformation
of the proton beam to the projection of the target. Right: Range compensator for
distal conformation - each point in the device has a different thickness to adjust
penetration depth at each point of the beam’s cross section.
Delivery mode number two, beam scanning, makes use of the proton’s electrical
charge. The basic idea is to sweep a proton beam across the target using magnets.
Beam scanning can be subdivided into uniform and pencil beam scanning (PBS). The
prior method still uses customized collimators and range compensators to conform the
dose since the scanned proton beam is large (several centimeters). At about 1 cm
full-width-half-maximum (FWHM) the diameter of the beam for PBS is significantly
smaller. In addition to the delivery of uniform dose per field (single field uniform dose,
SFUD) without custom hardware, this gives the freedom to perform intensity modulated
proton therapy (IMPT) by varying the delivered dose on a point-by-point basis. Beam
scanning is technically more challenging, and currently only employed by few proton
therapy centers. IMPT is performed by only one center (PSI, Villigen, Switzerland).
Various modes of IMPT have been proposed, characterized by the allowed number and
positions of beam spots [32]. Lomax concludes that full 3D optimization, i.e. permitting
spot positions throughout the entire target, best retains maximum flexibility in designing
dose distributions.
1.4 Scope of this work
The vast majority of patients treated with proton therapy up to date has received
passively scattered proton therapy. Although intensity modulation is inherent to the
delivery of a spread-out Bragg peak (SOBP), the dose to the target given per beam is
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homogeneous. For true intensity modulated proton therapy this is not the case, target
dose is uniform only after the delivery of all beams for a fraction is completed.
In photon therapy intensity modulation is most commonly provided by varying beam
shapes with multileaf collimators. Current development in proton therapy makes use of
the electrical charge of the particle by sweeping a small beam of 1cm diameter across the
target with magnets. Beam scanning enables three-dimensional intensity variation on a
point by point basis.
Scanning systems are technically challenging and currently not standard equipment
for existing proton therapy facilities, and passive scattering systems will therefore be of
use in the near and intermediate future.
We are presenting a feasibility study for the application of multileaf collimators for
intensity modulation in passively scattered proton therapy.
Computational studies are reported in chapter 2. Chapter 3 contains experimental
investigations.
The following issues are addressed:
• Can IMPT in fixed beamlines offer advantages with respect to conformal (passively
scattered) proton therapy? (Section 2.1)
• Is it feasible to deliver IMPT with an MLC, considering treatment time and neutron
dose? (Section 2.2)
• What are the properties of a multileaf collimator in a proton beam? (Section 3.1)
• What is the relationship between peak dose per monitor unit (output) and collimator
size? (Section 3.2)
Chapter 2
In Silico Studies
This chapter contains studies concerning motivation for and feasibility of the use of
multileaf collimators for intensity modulation in proton therapy.
In contrast to IMRT, IMPT is not usually associated with multileaf collimators. The
ability to sweep protons across a target by magnets makes pencil beam scanning the
natural choice for IMPT. Most important benefit of this delivery method is the flexibility
to alter beam intensity at any point in the target without the need for custom hardware.
The majority of the equipment in the treatment nozzle used for passive scattering is
unnecessary for beam scanning. In pencil beam scanning the amount of material within
the beam path in the nozzle (and therefore the energy loss) is very small. The neutron
dose to the patient is therefore practically reduced to the neutrons created internally in
the patient. Custom made hardware for all fields is not strictly required, but has been
suggested for minimizing penumbra (for shallow depths with a custom milled collimator
[28]) and reducing the number of range layers (using a range compensator).
Much like in IMRT it is possible to employ an MLC for IMPT. This could be done in
conjunction with uniform scanning, i.e. delivering homogenous dose per range layer, or
passive scattering. The main difficulty for this method is the increased number of monitor
units due to the fact that target dose is delivered by mulitiple small segments for each range
layer, with a large fraction of the protons per segment being stopped in the collimator.
This translates into increased neutron dose to the patient and increased treatment delivery
time. Technically, however, this delivery method is much less challenging to implement
than IMPT by means of pencil beam scanning. It does not necessitate alterations of
the beamline or treatment nozzle, but only the add-on of the MLC device itself. For
passive scattering delivery, an additional benefit is decreased impact of interplay effects
for moving targets.
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Most of the currently existing facilities operate at least in parts with passive scattering
proton therapy. Facilities that are under development or in the planning phase do not
exclude passive scattering, so it is likely that this delivery mode will still be in use in the
near and intermediate future. In addition, facilities commonly feature one or more fixed
passive scattering beamlines. These are especially limited in terms of dose conformity.
Section 2.1 investigates the dosimetric benefits of using IMPT, particularly in the
context of fixed horizontal beamlines, and therefore gives motivation for exploring IMPT
delivery techniques. Subsequently in section 2.2, where IMPT treatment plans are
segmented for application of an MLC, and segmenting results, including neutron dose,
are evaluated.
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Figure 2.1: Patient rotating in the postioner of the fixed horizontal beamline at the Franic
H. Burr Proton Therapy Center, Boston, MA. Rigid immobilization of the head
as well as additional immobilization of the body is required for rotation of the
patient around the cranio–caudal axis. The speed of rotation is about 40 seconds
for 90 degrees. The patient is stationary during beam delivery.
2.1 The benefit of IMPT in fixed beamlines
2.1.1 Introduction
The application of a fixed proton beam has inherent advantages in regards to ease and cost
of construction and maintenance compared to a fully rotational gantry, but comes at the
potential expense of reduced selection of incident beam angles depending upon the range
of motion of the patient positioner. While it has been assumed that maximal freedom
in incident beam direction is a necessity for the vast majority of intensity modulated
proton therapy (IMPT) treatments, the use of IMPT with restricted beamline angle
selection has not been evaluated in detail. The Francis H. Burr Proton Therapy Center
(Boston, MA) features a fixed horizontal beamline for intracranial targets, and two fully
rotational gantries. For treatment in the fixed beamline patients undergo careful triaging
since treatment fields outside the coronal plane involve rotation of the patient around the
cranio–caudal axis. This is enabled by the patient positioner [33] but adds strain on the
patient and increases treatment time due to the required immobilization (Figure 2.1).
Due to the lack of proximal conformity of the spread–out Bragg peak passive scattering
dose distributions are fairly sensitive to incident beam angles. Favorable beam directions
usually involve minimum variation of target extension in depth direction, see Figure
2.2. For the majority of cranial patients this results in (at least) a treatment component
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Figure 2.2: An example for the quality of proximal conformity with passive scattering for
two beam directions. The dose distribution in (a) was calculated with a right
lateral field, (b) used a right anterior field. Using the oblique entrance angle
improves conformity due to minimum variation of the radiological depth of the
target. The yellow line indicates the 90% isodose level, the red line represents the
target structure.
outside the coronal plane. In addition, when high doses are delivered to targets in close
proximity to critical structures, treatment planning for passive scattering may necessitate
patch combinations with two or more fields to create concave dose distributions [34]. In
these situations a fully rotational treatment head is beneficial.
In an IMPT treatment plan dose can be flexibly distributed amongst fields and within
each beam. The issue of proximal non–conformity does not exist, and shaping of complex
dose distributions becomes much easier. We seek to understand whether this flexibility
makes IMPT dose distributions less sensitive to the choice of beam angles. Compared
to gantries, fixed proton beamlines have the advantage of lower cost and simplicity in
regards to construction and maintenance. Our work suggests that the main limitation
of fixed beamlines – the restriction of beam angles and therefore compromise of plan
quality - may be mitigated by the application of intensity modulated proton therapy.
2.1.2 Methods and Materials
This work presents a treatment planning study comparing various plan scenarios for a
group of 11 patients.
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pat # Diagnosis Volume [cc] Dose [Gy RBE] Location
CTV/GTV/boost CTV/GTV/boost
1 Low Grade Astrocytoma 64 54.0 Cerebellum
2 Meningioma 27 50.0 Right (Rt) Orbit
3 Acoustic Neuroma 3 54.0 Left (Lt) Cerebello-
pontine Angle
4 Meningioma 14 50.0 Lt Anterior Pontine
5 Meningioma 28 50.4 Lt Temporal Lobe
6 Anaplastic Ependymoma 80/32/5 48.6/52.2/57.6 Posterior Fossa
7 Adenoid Cystic Carcinoma 59/4 66.0/76.0 Nasal Cavity
8 Chordoma 26/16 65.0/72.0 Clivus
9 Chordoma 20/13 70.0/77.4 Clivus
10 Meningioma 5 50.4 Rt Cavernous Sinus
11 Chordoma 136/84 70.0/78.0 Clivus
Table 2.1: Patient selection diagnosis, target size, prescription dose and target location.
Patient Selection
This study is limited to intracranial targets only. Patients were chosen as a representative
mix of indications typically seen at the Francis H. Burr Proton Therapy center, with
regards to size, shape and prescription doses (see Table 2.1 and Figure 2.3). All dose
distributions and dose metrics in this work are presented in units of Gy(RBE), i.e. dose
in Gray corrected for radiobiological effect [35].
Treatment Plan Setup
Four treatment plans are compared for each patient: three IMPT plans with varying
beam angles and the treated passive scattered (PS) treatment plan as used for actual
treatment. Figure 2.4 depicts the allowed beamline configurations for scenarios IMPT A,
B and C. All scenarios permit couch rotation in the horizontal plane only. A full example
for one patient is explained in Figure 2.5 and Table 2.2.
Plans A utilized a fixed horizontal beamline. In combination with couch rotation
this results in beam angles restricted to the coronal plane. Plans B expanded on this by
allowing beamline angles in 45 degree increments, and Plans C allowed for a continuous
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Patient 1 Patient 2
Patient 3 Patient 4
Patient 5
Patient 6
Patient 7
Patient 8
Patient 9
Patient 10 Patient 11
Figure 2.3: The patient selection covered a wide range of target sizes, shapes and locations.
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Figure 2.4: Allowed beamline configurations for IMPT treatment plans. A: horizontal beam-
line, B: beam in increments of 45 degrees, C: continuous spectrum of gantry
angles. All scenarios employed a treatment couch for rotating the patient in the
horizontal plane.
spectrum of beamline angles, simulating a fully rotational gantry. Plans C use the same
beam directions as the passively scattered treatment plan; though in most cases only a
subset of the latter was necessary (for example for patch beam combinations).
beam plan gantry angle [deg] couch angle [deg]
1 A 270 10
B 315 0
C 280 0
2 A 270 90
B 180 0
C 180 0
3 A 90 -10
B 135 0
C 100 0
Table 2.2: Gantry and couch angles as used for plans A, B and C for patient 1. The
corresponding incident beam directions are visualized in Figure 2.5.
While PS plans were produced using CMS XiO 1 the IMPT calculations were generated
using an in–house developed software Astroid [36]. The latter employs multi–criteria
optimization, and hence enables the user to choose from a large library of treatment
1CMS Inc., St. Louis, MO
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Figure 2.5: Visualization of beam angle configurations in axial (left), coronal (center) and
sagittal (right) views for patient one to exemplify the treatment plan setup for
plan A (upper, beam angles only in coronal plane simulating a fixed horizontal
beamline), B (middle, gantry angles allowed in 45 degree increments) and C
(lower, free choice of gantry angles). Blue arrows represent incident beams, semi-
transparent arrows indicate beam angles not parallel to the plane of the image.
Corresponding gantry and couch angles are listed in Table 2.2.
In Silico Studies 23
Figure 2.6: The treatment planning system Astroid [36]. The panel on the left hand side
allows the user to browse through a library of treatment plans by moving sliders.
plans generated to fulfill the given constraints with the specified objectives for target
coverage and healthy tissue sparing [37]. Figure 2.6 shows the graphical user interface
for Astroid, displaying a treatment plan for patient #4 in this study. The minimum spot
size used was 5 mm sigma, defined in air at isocenter for the highest proton energy in
the beam data library.
IMPT plans were calculated on the same image data set with 1.25 or 2.5 mm slice
thickness, and on the same dose grid (1.25 × 1.25 × 1.25 mm3) as the clinically used
passive scattering plan.
For any plan comparison one has to choose a common denominator. This work
utilizes the generalized equivalent uniform dose (gEUD) to the target volume(s) as
delivered by the original PS treatment. Thus, the treatment planning goal for IMPT
dose distributions was a gEUD that most closely approximated the PS planned value.
According to Niemierko [38] gEUD is calculated as:
gEUD =
(∑
viD
a
i∑
vi
)1/a
(2.1)
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Table 2.3: Parameter a used for gEUD calculation
structure a structure a
Brainstem 12 Lacrimal Gland 12
Chiasm 10 Spinal Cord 10
Cochlea 20 Cerebellum 20
Frontal Lobe 10 Parietal Lobe 10
Temporal Lobe 10 Occipital Lobe 10
Lens 6 Parotid Gland 6
Optic Nerve 11 targets -11
Retina 10
where Di is the dose delivered to the target volume element vi, and the parameter
a describes the volume of interest. Target volumes are assigned a negative a, thereby
especially penalizing underdosage. Normal tissues have positive a parameters to emphasize
the high doses. Table 2.3 list values used in this study, as provided by A. Niemierko.
With the constraint of maintaining gEUD to the target, the dose to organs at risk was
minimized as much as possible. This is generally a difficult task, since it is impossible
to determine whether best possible solution has been achieved. Using MCO, however,
enables the treatment planner to easily evaluate a large number of treatment plans
that fulfill the general constraints, and therefore increasing the probability of reaching
a solution close to optimum. It is important to point out that although the PS dose
distribution was used as a baseline for comparison it is not assumed this represented the
gold standard of passive scattering treatment plans. Because of the current nature of
PS treatment planning – forward, with much time–consuming manual intervention and
iteration – the outcome is more subjective and more likely not fully optimized.
Plan comparison
All evaluated quantities were derived from dose–volume histograms (DVHs). The data
analysis consisted of three major points:
a) Quality of the dose distribution within and in proximity of the target. This was
assessed by means of conformal index (COIN) and homogeneity index (HI). COIN
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evaluates underdosage as well as quality of conformity, it is calculated according to Baltas
et al [39] as
COIN =
VGTV ref
VGTV
∗ VGTV ref
Viso ref
(2.2)
with
VGTV ref : the volume of the GTV receiving at least the reference dose (in this work the
prescription dose is used as reference)
VGTV : the volume of the GTV and
Viso ref : Total volume receiving the reference dose.
The Homogeneity Index in this work is defined as
HI =
D5 −D95
Dmean
∗ 100% (2.3)
with Dmean the mean target dose and D5 and D95 the dose to 5% and 95% of the
target volume, respectively.
b) Dose to organs at risk whose dose constraints had a direct impact on the quality of
the plan. The gEUD was calculated for each OAR and plan setup.
c) Dose to healthy brain tissue. The gEUD received by the surrounding healthy brain
was calculated for a subset of three patients. Chosen were cases most likely to present a
difference between the IMPT treatment plans (i.e. target located inferiorly in the cranium).
Brain lobes and cerebellum were delineated on one CT dataset by a neuroanatomist.
Deformable registration software (Plastimatch [40]) was used for registering the existing
structure set to the remaining two patients.
A data set of this size is difficult to evaluate by plotting DVHs and comparing
numbers in large tables across plans and for multiple patients. Therefore all DVH data
was summarized into single parameters for each property of the dose distribution (COIN,
HI, gEUD). The resulting graphs are no longer patient specific, but rather display results
for the entire patient cohort. This was achieved by indexing target volumes, organs at
risk and large brain structures, and plotting results versus structure index. Patients had
one to three target volumes for a total of 17 targets.
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Presented graphs visualize the difference of the evaluated quantities for IMPT plans
with respect to the PS value. This, again, does not intend to stylize the latter as the
gold standard and best possible passive scattering solution, but rather as a clinically
acceptable (and accepted) reference. In addition to the main objective of this work,
the inter–comparison of IMPT A, B and C, it also provides a comparison between the
two modalities PS and IMPT. Each treatment plan was in addition assessed for clinical
acceptability by a radiation oncologist by means of slice-by-slice evaluation of isodose
lines.
There is a certain randomness to treatment planning, in that the user specifies
objectives and constraints, beam angles, aperture shapes, etc. In short, there are many
variables that are manually controlled and it relies upon the planner’s judgment to
determine when further improvement of a dose distribution is impossible. The data
analysis therefore focuses on the composite results for the entire patient cohort, rather
than discussing differences on a per patient basis. Specific justification of single data
points has been explicitly avoided.
2.1.3 Results
Dose to targets
Considering all 11 patients the gEUDs to target volumes were within 1% (one standard
deviation) of the PS plan. The planning goal – a common gEUD between all plans – is
therefore considered fulfilled, and a meaningful comparison of dose distributions can be
performed.
The conformal index (COIN), describing dose conformity as well as under–dosage, is
depicted in Figure 2.7: Target volumes were sorted by size and the absolute difference
in COIN for the IMPT plans with respect to the PS plan plotted. The most striking
observation is that all three IMPT plans provide equal coverage and conformity. On
average there is a slight improvement of COIN for IMPT versus PS, but the standard
deviation is slightly larger than the difference itself.
Conformity of IMPT dose distributions is challenged especially for small targets by
non-optimal coincidence of target volume and spot placement grid, because the grid
resolution is large compared to target size. Lesions located in low density regions, such
as the nasal cavities (patient 7), are affected as well, since radiological distances translate
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to large geometrical distances. Therefore conformity for IMPT doses is best with larger
volumes and in homogeneous higher density media
The absolute difference in HI in percent of target mean dose for IMPT versus PS is
visualized in Figure 2.8. The data show no systematic variation between IMPT plans
A, B and C. Averaged over all targets there is no significant difference between IMPT
and PS. Inter–patient changes of ∆HI(IMPT − PS) are attributed to subjectivity of
planning, which we consider, in its effect, analogous to statistical noise. No general trend
with target size is visible.
Dose to organs at risk (OAR)
The OAR were indexed and sorted with respect to patient ID. Figure 2.9 visualizes the
absolute differences of gEUD for IMPT and PS dose distributions.
There is an overall improvement in gEUD to the OAR of 4.8 to 5.2 Gy for the IMPT
treatment plans as compared to the PS plans, with a fairly large standard deviation of
4.8 to 5.5 Gy. Of importance, the dose to organs at risk did not depend on the incident
beam angles for IMPT doses: Plans A, B and C are equivalent in regards to dose to
critical structures.
The difference in dose to critical organs between PS and IMPT plans had a large
standard deviation. This is mostly due to large reductions achieved for small organs at
risk. Reducing dose to small structures was relatively easy in our MCO based IMPT
planning software. The MCO software interface utilizes sliders to navigate between
treatment plans that fulfill given constraints. The preferred compromise of dose delivered
between target and critical structures can often be easily achieved when critical structures
have small volumes, resulting in little or no compromise to target dose. The largest
reductions in gEUD as depicted in Figure 4 are therefore seen for the smallest structures,
such as chiasm and cochlea. Overall, all IMPT plans spared OAR equally well. When
evaluating the data in Figure 2.9, it should be emphasized that the data was analyzed as
a composite. Differences between IMPT plans A, B and C in single data points are seen
but do not represent significant variation for the entire patient cohort. The objective of
this study is to identify general trends in the data that are not affected by single outliers
and random variations. Given the size of the data set this is a feasible approach.
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Dose to brain lobes
Dose to frontal, temporal, occipital and parietal lobes as well as the cerebellum was
assessed for three patients. In Figure 2.10 differences in generalized equivalent uniform
doses are plotted versus structure index, sorted by patient ID. The x–axis is labeled with
the name of the respective structure. In addition, structures labeled with * indicate that
a target is contained within them, resulting in the gEUD to be dominated by high dose
in proximity to the target, rather than by a low dose bath. This also affects structures
directly abutting a target (labeled with **). While for one patient there is a significant
increase in the gEUD to superior portions of the brain, the other two do not show
such general change; dose is rather distributed differently across the brain. Appreciable
increase in dose to healthy brain for IMPT plans A is expected for large targets located in
the cranial base, which are ideally irradiated with beam directions in the axial plane only,
in order to avoid non-target brain tissue (an example is shown in Figure 2.5). This is
reflected in the data. For patients # 3 and #11 all treatment plans A, B and C included
beam directions in the coronal plane, delivering dose to superior portions of the brain. In
these situations IMPT A does not deliver more dose to healthy brain than plans B or C.
2.1.4 Discussion
A study assessing the sensitivity of IMPT dose distributions towards the choice of beam
angles was presented.
Target gEUD, dose conformity and homogeneity did not differ significantly for the
three evaluated IMPT plan scenarios. Dose to organs at risk was slightly decreased for
IMPT compared to PS treatment plans, but did not differ amongst IMPT calculations.
Larger targets located in the cranial base are treatable with fixed horizontal beamlines,
but possibly at the cost of higher dose to healthy brain for a subset of patients.
This limitation of the single fixed horizontal beamline observed for cranial base cases
will likely hold true for extra–cranial targets: limiting incident beam directions to the
coronal plane will necessitate much larger treatment depths, and will increase the overlap
between beams. This is due to the cylindrical shape of the torso. IMPT plans A therefore
will likely not be clinically acceptable for the majority of extra-cranial targets. IMPT B
however may still provide dose distributions equivalent to what could be achieved with
free range of incident beam angles.
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The study did not evaluate plan robustness. It has been shown that quality of the
nominal plan degrades under robust optimization [41]. It is possible that, once plans
are optimized including robustness criteria, a difference between IMPT A, B and C
may be found. Dose calculation uncertainty is specific to treatment depth and degree
of inhomogeneity traversed by the beam. This could potentially be increased for plans
A since the available beam directions might not allow avoidance of inhomogeneities.
Furthermore IMPT A plans may require larger ranges. This will increase the absolute
range uncertainty as this is a consequence of HU to stopping power conversion and
general HU uncertainties. These are in clinical practice considered to be proportional to
radiological depth. Similarly, the small dosimetric differences noted for the IMPT versus
PS treatment plans may change in the face of uncertainties.
The literature suggests that larger improvements can be noted for IMPT versus
PS when using smaller spot sizes [42] [43]. This is due to the availability of steeper
dose gradients and therefore better dose conformity. Steep gradients on the other hand
negatively influence plan robustness [41].
Although there is no published study dedicated to a comparison of passive scattering
and IMPT, MacDonald et al [44] [42] concluded there may be improvements of dose
to OAR for IMPT in a comparison of three patient treatment plans. Multiple studies
performed at the Paul Scherrer Institute (Switzerland) compared PBS single-field uniform
dose (SFUD) with passively scattered SFUD dose distributions [45] [46], and later PBS
SFUD to IMPT [47] treatment plans. In those three publications, no significant differences
between PS and PBS SFUD doses were noted, while IMPT improved OAR sparing
compared to PBS SFUD.
A more thorough investigation than the one presented here may be feasible with a
beam angle optimization [48] [49] framework that incorporates fluence optimization into
the process. This may enable fast evaluation and comparison of a large number of dose
distributions obtained with various sets of beam angles.
Conclusion
IMPT dose distributions in this study were not sensitive to the choice of beam directions
when evaluating dose to the target and organs at risk. The patient sample included a large
spectrum of intracranial indications in terms of target size, location and prescription dose.
This gives good indications that it will be useful to add the capability for application of
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intensity modulation to facilities with existing fixed passive scattering beamlines. IMPT
overcomes the dosimetric limitations that exist for passive scattering in situations with
limited beam angles and will therefore increase the spectrum of indications treatable in
a fixed beamline.
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2.2 MLC based IMPT - A feasibility study
2.2.1 Introduction
The previous chapter illuminated the benefits of intensity modulated proton therapy
especially in fixed proton beamlines. There are two approaches to actually implement
IMPT - by means of scanned pencil beams or, as common in photon therapy, using a
multileaf collimator. The advantages of the latter are that it is a proven technology (for
photon therapy) and the absence of a need for modifications of the proton beamline itself.
The multileaf collimator can be implemented as an add-on module. This is especially
useful for retro-fitting existing passive-scattering proton beamlines for IMPT applications.
In the following, an approach to calculate and evaluate intensity modulated proton
beam plans for the delivery with a multileaf collimator (MLC) is presented.
In photon intensity modulated therapy beam-on time is increased compared to 3D-
conformal therapy since the dose for a beam is now delivered by a sequence of small
subfields, together constituting a 2-dimensional intensity map. In proton intensity
modulation there is one such two-dimensional intensity map per range layer. This may
increase the beam-on-time even more. Not only is this an issue of efficiency and treatment
time, but also of secondary dose to the patient. As discussed in the introduction, Chapter
1, protons undergo nuclear interactions when traversing through media. Neutron dose has
been the subject of constant debate in proton therapy, especially in the recent years [50]
[51]. A possible increase in neutron dose is an undesired side effect if intensity-modulated
proton therapy is applied with a multileaf collimator. A separate section was therefore
dedicated to the detailed discussion of this aspect.
2.2.2 Methods and Materials
Patient Selection
This study is restricted to lesions located in the cranium, because those are the cases
treated in our fixed beamline in which we are considering to apply a multileaf collimator.
The patient cohort is comprised of six cases, with diversity in intra-cranial target
locations, sizes and prescription doses (see Table 2.4).
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pat # Volume [cc] Dose [Gy RBE] Location
CTV/GTV CTV/GTV
1 27 50.0 Rt Orbit
2 14 50.0 Lt Anterior Pontine
3 28 50.4 Lt Temporal Lobe
4 19/12 58/68.0 Clivus
5 24/9 54.0/58.0 Base of Skull
6 123/78 72/78 Clivus
Table 2.4: Patient selection - target size, prescription dose and target location.
Planning Techniques
For a detailed description of the treatment planning system employed for this work,
Konrad, the reader is referred to Nill [52]. Treatment planning in Konrad begins with
setting up isocenter, beam directions and dose constraints for targets and organs at risk.
The cross section of a proton beam is divided into beamlets whose positions in beam’s
eye view are spaced according to a grid with a resolution set by the user and defined in
the isocenter plane. For proton therapy there is one such grid per energy used in the
treatment plan. One pencil beam is sent through each grid point, and dose contributions
from all beamlets i to all points j are calculated and stored in a matrix Dij, the dose
influence matrix.
This calculation is based on a library of pristine Bragg peaks generated by Monte Carlo
simulation, see Figure 2.11 [53]. The dose distribution of a pristine peak is determined
by the beam’s energy and angular distributions. Both depend on machine characteristics
as well as the properties of the traversed medium. In practice, the data library contains -
as a function of depth - both angular sigma and the dose deposited for each pristine peak.
A beam data library is commonly described by the sigma in air of the angular spread for
the deepest peak in the data set. This is the minimum beam width for the ensemble,
since higher energy protons are less affected by scatter in air prior to incidence on the
patient. The library of pristine Bragg peaks used for this publication had a minimum
beam sigma of 5 mm, and contained peaks with ranges in 5 mm increments.
Utilizing Dij the optimizer iterates the weights of all beamlets i until an objective
function, describing the difference between current and desired dose distribution, is
minimized. At the end of the optimization the dose distribution for a beam is characterized
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Figure 2.11: The Konrad beam data library. For clarity of the graph only every other peak
is displayed. Left: Depth dose curves. The dose at each depth represents the
integral dose in the plane at that depth. All curves are normalized to a weight
at peak depth of 10000. In a gaussian distribution the maximum peak height
equals the integral divided by a factor σ
√
2pi Right: Angular sigma of the pencil
beams as a function of depth.
by i beam spots with a certain energy, beam weight and position (x and y in beam’s eye
view coordinate frame). In Konrad these parameters are stored in ”steering” (energy
and spot position) and ”beam weight” (spot weight and position) files.
Figure 2.11 shows that at depths of interest up to 20 cm the beam sigma in out data
set is about 7 mm. According to Bortfeld et al [54] the optimal sampling resolution is
about one sigma of the considered pencil. We chose a spot grid resolution of 10 mm
with the aim to simplify the resulting intensity maps. The impact of compromising
the sampling distance to this extent, however, is not expected to have an appreciable
influence on the dose distribution, given the fact that intensities are optimized over
multiple beams at the same time. In order to validate that this does not compromise
the dose distribution treatment plans were optimized with both 7 and 10 mm spot grid
resolution.
It is important to note that this study does not address the deliverability with any
one specific multileaf collimator. Certainly the physical properties, such as leaf width or
leaf end shape, have a significant impact on the dose distribution. This work, however,
provides an initial feasibility study to assess whether the delivery of intensity modulated
dose distributions can be quantized in a way that permits the use of a multileaf collimator.
As mentioned above the optimizer can utilize pristine peaks from a library with 5 mm
spacing in depth. This results in a large number of range layers in the target. Aiming
to reduce the number of layers utilized for the calculation a third optimization was
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Figure 2.12: The modified Konrad beam data library. Displayed is every other peak for
clarity. Left: The optimization is now based on a series of 2-peak SOBPs. Right:
Sigmas for the new peaks were approximated by the weighted average of the
two sigmas at each depth. The weights of the peaks were obtained through an
optimization of depth dose homogeneity in the peak region.
performed on the basis of a data library based on small, two-peak SOBPs rather than
pristine peaks. Since now one range layer can provide dose coverage over a larger extent
in depth than was possible with a narrow pristine peak fewer range layers are needed to
produce dose distributions in accordance with the given constraints. To force Konrad to
use only every other peak from the beam data library it was necessary to use the steering
files obtained during the previous optimization (10 mm grid resolution, single pristine
peak data library), eliminate spots of every other energy, and optimize based on these
sparse steering files. The purpose of this third optimization is to investigate whether a
reduced number of range layers results in reduced number of segments while maintaining
equal plan quality as for the original number of range layers.
In order to sequence the intensity distribution for a beam for the delivery with a
multileaf collimator the beamlet intensities were first sorted according to energy and
then arranged in a matrix according to their position in the beam’s eye view coordinate
frame. The result was one intensity map per range layer.
During optimization in Konrad there are no constraints on the complexity of the
intensity distribution. The only limits are the spot positions and the quality of the
beam data library. To reduce the complexity of intensity maps produced during the
optimization process, however, the intensity maps are pre-processed prior to segmentation.
The aim is, again, to sequence intensity distributions with as small a number of segments
as possible. The less modulated an intensity map, the fewer segments are needed.
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Figure 2.13: An example for simplification of an intensity layer. Left: Original intensity
map for one layer (arbitrary units). Right: Simplified map after pre-processing.
Allowed were only two intensity levels for this layer. During the calculation
these two are first set to the minimum non-zero and the maximum value of the
original map (here: 159 and 874). Then all values are grouped with respect to
the one discrete intensity level they match most closely (group 1: 874 and 639;
group 2: 280, 368, 232, 159, 506 and 439). Their beam weight was subsequently
set to the group average (757 and 331), and finally the segments assigned their
respective, new values. This map is now deliverable in two segments.
Pre-processing was performed on a beam-by-beam basis. Each range layer was assigned
an importance based on its absolute dose contribution and dose variation within the
layer. Limiting the total number of intensity levels over the three-dimensional intensity
cube, the number of intensity levels per range layer was proportional to the importance
of this layer. In this step, at least one intensity was permitted per layer, no layer was
omitted.
Within a range layer, the intensity levels were first distributed at equal increments
between and including the minimum non-zero and maximum beamlet weight (with zero
as an additional allowed value). Next, beamlets were grouped with respect to the one
discrete intensity level they match most closely. Their beam weight was subsequently set
to the group average, resulting in non-uniform spacing between intensity levels. This is
demonstrated with a simple example in Figure 2.13.
Figure 2.14 shows the graphical user interface programmed in MATLAB2 for the
purpose of segmenting intensity maps that were calculated from Konrad optimization
output data (beam weight, spot position and energy) and beam data. The GUI was used
2The MathWorks Inc., Natick, MA
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Figure 2.14: Matlab GUI for segmentation of intensity maps created from Konrad beam
weight files, steering files and beam data library. Neutron dose is estimated for
passive scattering and MLC based IMPT delivery.
to steer and evaluate segmentation results, such as global and layer specific statistics for
a beam, as well as calculation of an estimate for neutron dose.
The preprocessed maps were then sequenced using the algorithm by Engel [55], as
implemented by Kofi Deh. The required number of segments is reported. Those segmented
intensity maps were read back into Konrad, so that the final step in the planning process
was dose calculation based on the newly determined intensity distribution.
This procedure was an iterative one - the beams were re-segmented until the desired
compromise between plan quality and number of segments was achieved. For this purpose
doses were compared with an approach similar to the method used in chapter 2.1. Targets
were indexed and gEUDs for targets and OAR as well as homogeneity index for targets
plotted. A segmented dose distribution was considered acceptable if target gEUD agreed
within 2.5% and HI within 5% of the original plan.
In summary, five dose distributions were calculated: Optimization I was performed
with a 7 mm spot grid resolution. For later segmentation plans II were optimized with
a resolution of 10 mm. For plan III we modified the beam data library and optimized
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plan # I II III IIs IIIs
spot grid resolution 7 mm 10 mm 10 mm
II segmented III segmented
beam data library 1pp 1pp 2pp
Table 2.5: Overview of calculated treatment plans. Numbers I – III are plans as optimized by
Konrad. Dose distributions for IIs and IIIs represent the resulting dose distributions
after segmentation of the Konrad optimized intensity distributions. 1pp and
2pp denote single pristine peaks and 2-peak SOBP Konrad beam data libraries,
respectively.
using mini-SOBPs and a grid of 10mm. Finally, plans II and III were sequenced and
dose re-calculated with the new, segmented intensity distributions, resulting in plans IIs
and IIIs. An overview of the various plans is given in Table 2.5.
Neutron Dose Estimate
Neutrons are an unwanted byproduct in proton therapy. There are three main sources of
neutrons: the beam modifying devices in the treatment nozzle, the beam limiting device
(aperture), and the patient. For our fixed beamline the contribution from the aperture is
the largest, and increases with smaller aperture size and higher beam energy. Using a
multileaf collimator for intensity modulation requires delivery of an increased number of
monitor units and smaller fields, with both factors increasing the neutron dose to the
patient.
We estimated the neutron dose resulting from a delivery of the calculated IMPT dose
distributions with a multileaf collimator. The neutron dose data as presented in section
3.1 served as a basis for calculating the estimate. In brief, neutron dose was measured
with Bonner spheres at multiple positions lateral of the central beam axis for various
proton energies and multileaf collimator openings. A quality factor of 5.9 was used for
the conversion to dose equivalent. Neutron dose for a given MLC segment was then
estimated by interpolating the data set given proton energy and are of the segment. The
reader is referred to section 3.1 for a detailed description on the measurements.
Using this dataset allowed us to accumulate the neutron dose contribution on a
segment–by–segment basis. Neutron dose to the patient strongly depends on the distance
from the collimator. Values given here represent the neutron dose at a distance of ≈ 75
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Figure 2.15: Absolute dose calibration of monoenergetic Bragg peaks for a 50 mm field radius
for the fixed horizontal beamline at the F.H.B proton therapy center.
cm off isocenter, perpendicular to the beam direction, a position relevant for the most
sensitive patient group, pregnant women. Neutron dose in forward direction is larger
than in lateral direction by a factor of ≈ 1.1 – 3 depending on proton energy and air gap.
IMPT. The energy and area of each segment was used for two-dimensional interpo-
lation of the data set given in Figures 3.7 and 3.8 to obtain the neutron dose per proton
Gray segment by segment. The total neutron dose given by any single beam is calculated
by summation of all segments’ contributions.
Passive Scattering. The IMPT neutron doses are contrasted to a similar estimate
for a passive scattering delivery. The minimum and maximum range needed for a beam
in the IMPT plan were used to estimate range and modulation needed to deliver a
homogeneous dose to the target via an SOBP. The number of pristine peaks constituting
this SOBP, their energies and number of monitor units were determined using LAMINATE
[56]. The dose per monitor unit at peak depth for monoenergetic beams was calculated
from a fit to measured data, see Figure 2.15. The field size was approximated by the
largest extent of a beam over all depths.
2.2.3 Results
Evaluation of dose distributions
To illustrate the degradation of dose distributions after segmentation, target dose volume
histograms for patient #1 and various segmentations of plan II are displayed in Figure
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Figure 2.16: Target DVH for patient # 1 as a function of the average number of segments
per beam. The DVH for the original non-segmented dose distribution is plotted
in solid red. Three beam directions were used for this treatment plan.
2.16. There were three beam directions in this plan. The legend indicates the average
number of segments per beam. A too large reduction in the number of segments leads to
severe degradation of the treatment plan. When utilizing a large number of segments,
the original dose distribution is reproduced, as is the case in Figure 2.16 for the average
of 126 segments per beam. Reducing this by ≈ 30 segments per beam caused a minor
degradation of the DVH for this plan. Sequencing with 79 segments per beam yielded
the best compromise between plan quality and segment number in agreement with the
constraints for gEUD and HI. Limiting the amount of segments even more degraded the
dose distribution to an unacceptable level.
Figures 2.17 and 2.18 show the quality of the resulting dose distribution using
optimization I (7 mm spot grid, original beam data library) as a reference. Target gEUDs
of all plans agree within 2.5% maximum deviation. The mean difference in gEUD with
respect to plan I was 0.03%, 0.06%, 1.03% and 0.78% for plans II, III, IIs and IIIs,
respectively. The homogeneity index, i.e. the width of the fall-off of the dose volume
histogram between the 5% and 95% dose levels of the target dose, proved to be the
more sensitive parameter. The average absolute difference in HI compared to plans I
was 0.73%, 2.19%, 1.59% and 3.04% for plans II, III, IIs and IIIs, respectively. That
means our segmentation of optimized plans caused ≈ 1% increase of the homogeneity
index. There were no significant differences with regard to dose to OAR. The differences
in the mean gEUD of the OAR between the plans were small compared to the standard
deviation.
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Figure 2.17: Left Upper: absolute generalized equivalent uniform dose (gEUD) for all target
volumes and plans versus target index. Left Lower: Differences in target gEUD
of all plans with respect to plan I. Right Upper: Homogeneity index (HI) for all
target volumes and plans versus target index. Right Lower: Differences in HI of
all plans with respect to plan I. Data points have been connected to guide the
eye.
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It was possible to produce plans within the defined acceptance criteria of ± 2.5%
target gEUD and ± 5% homogeneity index. How closely the segmented dose distributions
resemble the original optimizations depends strongly on the number of segments allowed,
see Figure 2.16.
Segmentation results
The average number of segments per beam for all patients is depicted in the left upper
panel of Figure 2.19. This number averaged to 73 and 40 for plans IIs and IIIs, respectively.
Per layer these numbers translate into 4.9 and 5.6 (Figure 2.19, left middle panel). In
total, over all beams, the average number of range layers was 49.3 and 23.7, respectively
(Figure 2.19, left lower panel).
Neutron dose estimate
The correlation of the relationship of neutron dose versus number of segments is illustrated
in Figure 2.20, as calculated for patient # 1 plan IIs. The curve levels off at ≈ 80 segments
per beam. This is a consequence of limiting the numbers of segments via a restriction of
the number of intensity levels. With only few intensity levels allowed there will be some
very large segments in a beam, but most of the dose is delivered by many small segments
that have a much larger contribution to neutron dose. With more intensity levels allowed
the histogram of total dose delivered by a field size in a beam shifts towards the medium
segment sizes, with fewer very small segments, and very few, if any, very large segments.
That means that per segment less neutron dose is delivered. This effect of field size
counteracts a continuous increase in neutron dose due to increased number of segments.
Per delivered proton Gray the neutron dose for the passive scattered plan and plans
IIs and IIIs was on average 0.1 mSv/Gy, 0.8 mSv/Gy and 0.6 mSv/Gy, respectively, as
shown in Figure 2.19, right middle panel. This corresponds to an average increase in
neutron dose for MLC based IMPT delivery by a factor of 6 - 8 (Figure 2.19, right lower
panel). For completeness, the total neutron doses over the entire treatment course are
plotted in the right upper panel of Figure 2.19.
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Figure 2.19: Left: Average number of segments per beam (upper) and layer (middle) as well
as the total number of layers in the plans for all patients (lower) are plotted.
Right: An estimate of the total neutron dose in mSv for the entire treatment
course (upper), per delivered proton Gray (middle) and the ratio of IMPT to
passive scattering values (lower). Values represent the neutron dose using a
tungsten multileaf collimator, at a position approximately 75 cm off lateral from
isocenter.
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Figure 2.20: For one patient (# 1) plan IIs was sequenced with a range of numbers of segments
per beam. Neutron dose in mSv per delivered proton Gray was estimated for
each case.
2.2.4 Discussion
Without constraining the number of segments the quality of segmented dose distributions
can be equal to the original. But, as expected, the quality of dose distributions decreases
if the complex IMPT intensity maps are sequenced into fewer segments. Our optimization
and segmentation approach resulted in acceptable treatment plans when using an average
number of segments per beam of 73 and 40 for plans IIs and IIIs, respectively. Taking
into account that typical intra-cranial IMPT plans consist of three to four fields this
corresponds to 210 – 280 (IIs) and 120 – 160 (IIIs) to be delivered for any treatment
fraction.
To put this into perspective we analyzed the step–and–shoot IMRT plans of 66
patients treated at our institute and planned with either the Corvus or the CMS XIO
treatment planning system (33 patients each). All patients were treated with a Varian
linear accelerator. The average number of segments per beam for Corvus and XIO was
50 and 22, respectively, while a typical plan consisted on average of 9 and 7 fields. This
results in averages of 450 and 150 segments per treatment fraction. The average treatment
times were 23 and 19 minutes for Corvus and XIO, respectively. These numbers indicate
that it is technically feasible to deliver the segmented IMPT treatment plans IIs and IIIs.
Neutron dose for IMPT delivery is increased compared to passive scattering by a
factor of 5 – 9 for IIs and 4 – 7 for plans IIIs. This translates into a maximum neutron
dose per delivered proton Gray of about 1.2 mSv at a distance of 75 cm of isocenter under
measurement conditions described in chapter 3.1. Neutron dose varies strongly with
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beamline design. In the fixed horizontal beamline at the F.H.B proton therapy center
measured neutrons dose are approximately an order of magnitude lower compared to our
gantry beamlines. Here the beam is always scattered to a diameter of 25 cm regardless
of the field size needed for treatment. For small fields this results in a large number
of protons stopped very close to the patient in the aperture. In the fixed horizontal
beamline (described in detail in chapter 3.1) the scatter diameter is 10 cm and therefore
much less particles are stopped in the collimator per delivered proton Gray. The issue of
beam efficiency through the collimator has recently been discussed by Hecksel et al [57].
NCRP 151 [58] reports on neutron doses per photon Gray for a variety of linear
accelerator models and energies with values varying between 0 to 2 mSv per photon
Gray at 1.4 m distance from the target. Usually IMRT applications utilize an energy
of 6 MV. This is below the threshold for neutron production, and hence the secondary
neutron dose is zero. Due to the increased number of monitor units in IMRT however,
the scattered photon dose is significantly increased. Athar et al [59] reported that at
relevant distances larger than 25 cm from the field edge IMRT dose is approximately 1
mSv per photon Gray.
Although an increase in neutron dose of a factor of 4 – 9 when applying IMPT
compared to SOBP treatments is undesirable, the absolute neutron dose to the patients
can be reduced to acceptable levels with careful beamline design. The neutron dose can
be further reduced by optimizing the design of the collimator itself [60].
This study represents an initial feasibility analysis for MLC based IMPT. Further
improvement of our results may be achieved by employing an optimizer specifically
designed for the task of MLC delivery with the goal of minimizing the number of
segments and neutron dose to the patient.
Conclusion
Our preliminary study indicates the feasibility of segmenting IMPT intensity maps for
treatment delivery by means of a multileaf collimator in a passive scattering proton
therapy beamline. Loss in plan quality can be maintained at an acceptable level while
reducing the required number of MLC segments. The increased flexibility in dose delivery
has to be weighed against an increase in secondary neutron dose to the patient.
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Since segmentation results in a requirement to deliver multiple small fields, for clinical
implementation, a comprehensive study of small field dosimetry is necessary (Chapter
3.2).
Chapter 3
Experimental Studies
The properties of a collimator, geometry and material composition, influence the dose
distribution. Exploring those properties is a necessary task on the way to implementation
of a multileaf collimator for beam delivery.
Section 3.1 describes the most important features of a mini-multileaf collimator1 in a
proton therapy beamline, in comparison to custom milled apertures used routinely. An
important part of those measurements are neutron doses for various field size, energies
and airgaps. This data set served as the basis for neutron dose estimate in section 2.2
As mentioned in previous chapters small-segment delivery is very common to MLC
based IMPT. Since charged particle equilibrium breaks down for smaller fields the dose at
peak depth changes with field size. The relationship of peak dose versus beam aperture
shape has to be known for accurate IMPT delivery. Section 3.2 contains a measurement
set that will serve as a basis for monitor unit calculation.
3.1 The dosimetric properties of MLCs in a proton
beam
3.1.1 Introduction
The majority of proton therapy centers use a passively scattered beam [61] [62] in
combination with a custom milled aperture and range compensator for final, per-field,
beam shaping. Torikoshi et al. [63] previously published on the application of a custom
1Integra Radionics, Burlington MA
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Figure 3.1: Side view of the STAR (STereotactic Alignment in Radiosurgery) beamline. From
left to right: bending magnet (A), quadrupoles (B), ion chamber 1 (C), beam
profile monitor (D), binary absorber system (BABS, E), range verifier (F), beam
stop (G), neutron shielding (H), ion chambers 2 and 3 (I), nozzle stand with xray
tube, cone and aperture (J), STAR patient positioner (K). The arrow indicates
the position of the mMLC. Not to scale.
multileaf collimator in their carbon ion therapy beamline. It is used as final collimator for
extra-cranial lesions, and has been commissioned for a layer-stacking [64] [65] technique.
Layer-stacking has been applied to a handful of patients and has since been discontinued
[66]. Ainsley et al [31] are employing Varian multileaf collimators in IBA gantry beamlines
for conformal proton therapy for large targets.
This work investigates the usability of a mini-multileaf collimator (mMLC) in passively
scattered proton beam therapy for intra-cranial lesions. The goal is to study the mMLC
as a replacement for custom milled apertures. We use a commercial mini-multileaf
collimator manufactured by Integra Radionics for which we explore the mechanical and
dosimetric properties.
3.1.2 Methods
Beamline
Figure 3.1 shows a schematic drawing of the STAR (STereotactic Alignment in Radio-
surgery) beamline. The beam direction in our intra-cranial beamline is fixed in the
horizontal plane. The 5-degree-of freedom patient positioner allows rotation and transla-
tion of the patient with respect to the beam isocenter. In combination with collimator
rotation, our system has the necessary degrees-of-freedom to achieve any beam direction.
A proton beam of fixed initial energy (185 MeV) is degraded and scattered by a
Binary ABsorber System (BABS, see Figure 3.2(a)) consisting of a set of ten lexan and
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Figure 3.2: (a) The binary absorber system BABS consists of 5 lead and 10 lexan blocks.
Brass apertures up- and downstream confine the beam laterally. (b) & (c) STAR
produces SOBP’s by consecutive delivery of pristine Bragg peaks. In the example
in (c) an SOBP with a range and modulation of 13.5 cm and 3 cm is produced
by a sequence of four pristine peaks. The black dot in (b) represents the virtual
source position. The blocks symbolize those lead (left of dashed line) and lexan
(right of dashed line) absorbers which are brought into the beam path to achieve
the desired pullback and angular spread [56]
a set of five lead blocks. Within each set the thickness of a scatterer equals half the
thickness of its upstream (lead) or downstream (lexan) absorber. Spread-out Bragg peaks
are produced by the consecutive delivery of single pristine peaks of different range and
weight, i.e. the dose is delivered range layer by range layer (Figures 3.2(b) and 3.2(c)).
BABS scatters the particles to a constant field diameter of 10 cm, and degrades the
initial energy to the desired treatment range between 2 and 19 cm in water and arbitrary
modulation.
The large source-to-axis distance (SAD, 460 cm) minimizes the impact of the source
size on dose, i.e. sharper penumbra and less pronounced effect of field size on output.
The beamline is commissioned to deliver a continuous range of proton energies and
modulations, allowing highly conformal treatment plans.
MLC system
The mMLC was constructed for the geometry of a clinical linear accelerator (LINAC)
with an SAD of 100 cm. The sixty-two tungsten leaves have a thickness of 73 mm and
a width of 2.225 mm at the upstream and 2.517 mm at the downstream face. Physical
aperture outlines formed by the mMLC measure up to 69 mm parallel to the direction of
leaf motion and 54 mm perpendicular. Tongue and groove construction of 0.3 mm limits
inter-leaf leakage while an additional step of 0.3 mm limits leakage between abutting
leaves. The control software for the mMLC is provided by Integra Radionics and runs
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on a Windows platform. The leaf positions for a treatment field are set according to an
input file, which is created by an external application.
Field Reproducibility An important factor for mMLC treatments is the accuracy
of the leaf motion. A rectangular shaped mMLC outline involving all leaves was set ten
times, measuring the field dimensions with x-rays acquired by a digital panel .
Field Shaping The leaves are tapered perpendicular to their motion direction to
sharpen the lateral dose fall-off for photons. Our beamline SAD of 460 cm results in
a smaller beam divergence compared to a LINAC with an SAD of 100 cm. Thus, the
downstream and upstream edges determine the field shape along and perpendicular to the
leaf motion respectively. We therefore need to incorporate the geometry of the mMLC
(taper and leaf thickness) and our beamline (SAD) into a leaf positioning algorithm. The
beamline SAD as a function of range is obtained by measurements of lateral profiles in
air at different distances from the source. The FWHM of these profiles was extracted
and extrapolated to zero width, which corresponds to the virtual source position. Since
the SAD varies with the type and amount of BABS material in the beam path, the SAD
has to be measured for a set of ranges. To minimize dose-averaging, in-air profiles were
measured with a mini-thimble ionization chamber with an active volume of 0.0073 mm3
constructed by Schreuder [67]. Given the SAD, the leaf settings for a field shape can be
accurately calculated. The leaf positioning algorithm was written and explained in detail
by Bangert [68]. In short, mMLC thickness and taper are considered by calculating leaf
settings for two infinitely thin collimators located at the upstream and downstream edge
of the mMLC. The above algorithm is applied to both, where the input contour is the
projected original contour. The final leaf position is the most retracted of the two. All
measurements are done with a 50% overlap of leaves and contour. The verification of the
leaf-positioning algorithm includes proton beam measurements with radiographic film in
air, for ranges of 4 cm and 18 cm, and a circular field shape of 5 cm diameter.
Measurements
Dose Distribution. The leaf width (≈ 2.5 mm) and the mMLC taper influence the
dose conformity, penumbral width, and scatter characteristics from the inner collimator
walls. The differences between brass and tungsten, however, are not expected to produce
a measurable difference. A possible difference in scatter might be reflected in a change
of the peak-to-entrance ratio for small fields. We therefore measured lateral and depth
doses for mMLC and brass aperture. Lateral doses were measured with Kodak XV film
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placed at the center of SOBPs with ranges of 18 cm, 12 cm and 4 cm and modulation
of 2 cm. Vertical and horizontal profiles through the spot centers were extracted and
compared. The response of radiographic film can be non-linear in both dose and proton
energy. To guarantee linearity, films were irradiated with no more than 30 cGy. This
limit is the result from unpublished measurements investigating the dose response for a
variety of energies. Monte Carlo simulations furthermore showed that the mean energy of
protons in the penumbral region changes only for doses below the 50% level. We therefore
use the 50-95% width to avoid impact of the energy response of film on our results. A
PTW N31006 pin-point ionization chamber (active volume 0.015 cm3) was used for depth
dose measurements in a Wellhoefer water tank for pristine Bragg peaks of ranges 4 cm,
12 cm and 19 cm and field diameters between 10 mm and 50 mm. Measurements of
small proton fields are generally difficult. The ideal detector would have linearity in dose
response, no energy dependency, and a small active volume to avoid dose averaging. The
latter could affect our measurements for the smallest field sizes. Two-dimensional dose
distributions for mMLC and aperture were obtained with radiographic film for 2 cm wide
SOBPs of ranges 4 cm and 18 cm. The film was placed in the center of the SOBP. The
effect of the leaf width on dose conformity was studied by means of γ–index analysis [69]
of aperture and mMLC shaped dose distributions. For this test we used an irregular field
shape forming a single beam as used in a clinical treatment plan. The dosimetric and
spatial criteria were 2% of the global maximum dose and 1.5 mm, respectively.
Proton Leakage, Neutron Production & Activation. Measurements were
performed to quantify equivalent dose, in Sievert per delivered proton Gray, to the
patient due to leakage protons and secondary neutrons. Activation of the tungsten leaves
was examined. The mMLC leaf thickness of 7.3 cm is twice that necessary to stop protons
of our maximum energy of 185 MeV. Hence, proton leakage is expected only where leaves
abut and not in between the leaves due to the tongue-and-groove construction and the
taper. Radiographic film was placed in air at isocenter, and a dose of 16 Gy delivered
with fully closed leaves. The shut-position of the leaves was altered such that leaves
abut outside the field. We expect a higher neutron flux from tungsten compared to
brass. Neutron measurements were performed with Bonner spheres (diameter 25.4 cm)
placed in a variety of locations inside and outside the treatment room. To assess upper
and lower limits of the neutron dose the experiment was conducted for pristine peaks
with ranges of 4 cm and 18 cm, with fully closed collimators as well as different sizes of
collimator openings while stopping the beam in a polyethylene block located at isocenter.
The activation of the closed mMLC was measured over a 24 hour time period with a
Geiger counter after the delivery of 16 Gy using a proton range of 19 cm.
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Figure 3.3: Due to the one-directional taper of the mMLC knowledge of the range dependent
SAD is crucial to accurately shape treatment fields with the mMLC. (a) Results
of our SAD measurements, the solid line is a fit to the data. (b) & (c) Film
measurements of proton dose distributions in air at isocenter (airgap 43 cm) for
R=4 cm and R=18 cm, respectively. The 50 % isodose line is printed solid, the
input field shape (in this case a circle of 5 cm diameter) dashed.
3.1.3 Results
MMLC
Field Reproducibility. The repeated setting of rectangular collimator openings showed
that the mMLC leaves reposition within a maximum uncertainty of 0.1 mm, i.e. the
measurement uncertainty (the resolution of the digital panel).
Field Shaping. Figure 3.3(a) shows the result of our SAD measurements. We expect
scattering to smooth the ragged collimator outline. Even in air, the scatter introduced
in BABS is sufficient to converge the mMLC outline at the 50 % isodose line to the
expected field outline. We thus compare the expected field shapes in-air to validate our
leaf positioning algorithm. Figures 3.3(b) and 3.3(c) show the proton dose distributions
in air for ranges of 4 cm and 18 cm, respectively, when aiming for a circular field of 5 cm
diameter. At the field edges the influence of the leaf width on conformity is visible; in
transverse direction the input contour is reproduced within half a leaf width. In all other
areas the ragged outline of the mMLC fields is washed out by scattering and agrees well
with the input contour. This is more so the case with increasing depth in the patient,
improving the conformity of the dose distribution.
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Figure 3.4: (a) Virtual source size (σ) versus range. (b) & (c) Transverse and longitudinal
lateral profiles for brass aperture and mMLC for ranges of 4 cm (b) and 18 cm
(c) and a field of 5 cm diameter.
Table 3.1: Lateral 50–95 % widths of dose profiles through the center of circular radiation
fields (in mm). For the MMLC transverse and longitudinal penumbra are given
but averaged for the brass aperture.
range [cm] brass aperture mMLC long mMLC trans
4 4.19 4.76 5.40
12 4.04 4.28 4.61
18 5.13 5.44 5.88
Dose Distribution
Lateral Profiles. Two factors determine the width of the lateral fall-off: virtual source
size and in-patient scatter. For low proton energies the source size dominates, while for
deeper ranges multiple Coulomb scattering, MCS, in the patient contributes most to the
spatial spread of the proton beam. Figure 3.4(a) displays the measured virtual source
size versus range in water.
We measured lateral profiles to evaluate penumbral widths. Table 3.1 compares
lateral 50-95% widths obtained for mMLC transverse (perpendicular to leaf motion)
and longitudinal directions, and the brass aperture averaged over both directions. The
penumbra is large at low energy due to the source-size increase, minimal at medium
ranges as in-patient scatter and source-size are small, and is dominated by MCS in the
patient at high range.
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Figure 3.5: Left: Depth dose curves for field diameters 25 mm and 10 mm, R=12 cm. Right:
Peak-to-entrance ratios versus field diameter for R=4, 12, 19 cm.
The finite leaf width results in a broader lateral fall-off for the mMLC by 0.2 mm to
1.2 mm (Table 3.1). The difference between transverse and longitudinal penumbra for
the mMLC is clearly visible, the 50-95% width in longitudinal direction (no taper) is
0.5 mm smaller than perpendicular to it. The lateral profiles in the longitudinal direction
(Figures 3.4(b) and 3.4(c)) show that the aperture and mMLC profiles agree within a
maximum deviation of 0.6 mm. Those differences decrease with depth. We kept, for
practical reasons, the airgap constant at 30 cm. In clinical practice brass apertures can
be brought very close to the patient (≈ 2 cm), while the mMLC will be positioned at a
larger distance to avoid collisions (≈ 20 cm). Due to the large SAD this only results in a
minor additional difference in the penumbra of a few tenths of a millimeter (if no range
compensator is present).
Depth Doses. Figure 3.5(a) shows central axis depth dose curves measured for mMLC
and brass aperture for R = 12 cm and field diameters of 25 mm and 10 mm. The
difference in entrance dose between the 25 mm and 10 mm diameter aperture is due to
lateral charged particle disequilibrium. A summary of all measured peak-to-entrance
ratios for various ranges and field diameters is given in Figure 3.5(b). The data show no
significant difference in range (≤ 0.5 mm), width (≤ 0.5 mm) and distal fall-off between
mMLC and aperture shaped depth doses. There are, however, slight differences in the
peak-to-entrance ratio for 10 mm wide fields of about 4% for 12 cm and 19 cm ranges.
This might indicate changes in collimator scatter due to material and geometry differences
of the two collimators. Measurement uncertainty, however, is increased for such small
fields.
Planar Dose Distributions. Figure 3.6 shows the γ–index analysis for a patient
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Figure 3.6: γ-index images comparing aperture and mMLC shaped dose distributions for
a realistic treatment field. The space and dose criteria were 1.5 mm and 2 %,
respectively. Leaf motion direction is up-down. Dashed (aperture) and solid
(MMLC) outlines represent the 90 % isodose line. (a) R = 4 cm, (b) R = 18 cm.
field with ranges of 4 cm and 18 cm and 2 cm modulation. The criteria (2% of the central
axis dose, and 1.5 mm) are met everywhere except in the field edges.
Leakage/Transmission
Proton Leakage. The developed and digitized film did not show any dose response.
Since doses above ≈5 cGy produce a visible response on the film, we conclude that, given
the delivered dose of 16 Gy, interleaf leakage is smaller than 0.3 %.
Neutron Production. We measured a neutron dose of 0.03 mSv/Gy to 0.13 mSv/Gy
for a closed brass aperture and a Bonner sphere located at isocenter, and 0.04 mSv/Gy
to 0.23 mSv/Gy for the mMLC (Figure 3.7, left). These numbers are on the very low end
of the range of data reported in the literature. References [70] [71] [72] [73] [74] [75] [76]
[77] [78] report on previous simulations and measurements of neutron doses at various
proton therapy institutions. Measurements in our double-scattering gantries using the
same detectors and a similar setup showed a neutron dose of 2.5 mSv/Gy at isocenter,
which is 10 times more than detected with the mMLC. Our results (Figures 3.7 and 3.8)
furthermore confirm the expected higher neutron doses in the tungsten mMLC (by a
factor of 1.5 to 1.8) compared to brass apertures. For the mMLC the typical airgap is ≈
20 cm and ≈2 cm for the brass apertures. Comparing neutron doses for those airgaps
(see Figure 3.7), one finds that in a clinical situation, because of the larger airgap, the
neutron dose would actually be less for the mMLC (≈ 0.32 versus ≈ 0.45 mSv/Gy for R
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Figure 3.7: Neutron dose per delivered proton dose versus lateral distance from isocenter.
The beam was fully blocked by the collimator. Left : mMLC and brass aperture
for R=4 cm and R=18 cm, airgap = 30cm. Center : mMLC for R=4 cm and
R=18 cm and various airgaps. Right : Brass aperture for R=4 cm and R=18 cm
and various airgaps.
= 18 cm). The out-of field dose in such a situation would be approximately equal in such
a case. Figure 3.8 shows a clear relation between collimator opening and neutron dose.
At a distance of 70 cm lateral to isocenter, the neutron counts are reduced by 40% for
the mMLC and 17% for the brass aperture when using the maximal field opening. In this
case the proton beam was stopped in a block of polyethylene, hence the measurements
include neutrons produced in the plastic.
Activation. The mMLC was monitored over a 24-hour period after the delivery of
16 Gy (Figure 10). A selfshielding effect of the mMLC is visible in Figure 10(a). The
activity at 1 m distance from the downstream side of the mMLC (dashed line) is lower
than at the same distance at a 90 degree angle to the beam direction. As even our
maximum energy protons penetrate only to half the leaf thickness, the remaining 3.5 cm
of tungsten act as shielding. Figures 3.9(b) and 3.9(c) simulate two days of delivery of
1Gy every 15 minutes for 10 hours a day, based on our measurements. At a distance
of 1m downstream of the collimator the activation reaches its maximum at ≈ 6× 10−4
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Figure 3.8: Influence of collimator opening on neutron dose. For comparison we included the
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Figure 3.9: (a) Activation of the mMLC per delivered Gray as measured with a Geiger
counter at various locations. Solid line: 2cm downstream of leaves, dashed line:
1m downstream, dash-dotted line: 1 m distance to mMLC at a 90 degree angle
to the beam. (b) & (c) Simulation of the mMLC activity over the course of two
treatment days, assuming the delivery of 1 Gy every 15 minutes for 10 hours
per day. (b) As measured at 1 m distance of the mMLC (in beam direction) (c)
measured at 2 cm distance to the leaves.
mSv/hr, at 2 cm distance at ≈ 4× 10−3 mSv /hr. After the 14 hour break the activation
was at background level ≈ 0.5× 10−4 mSv/hr.
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3.1.4 Discussion
Torikoshi et al. have reported on their custom-designed multileaf collimator for extra-
cranial treatments [66]. Their MLC consists of 6.5 mm thick steel leaves, and the device
is used as final collimation in their carbon ion therapy beamline. For increased lateral
conformity, intra-cranial lesions are still treated with custom milled collimators. We
validated the applicability of a commercially available mMLC for use in intra-cranial
proton therapy. The mMLC has been specifically designed for use in photon linear
accelerators; the choice of leaf material was based on attenuating photons, and the leaves
are tapered according to an SAD of 1 m. Our dosimetric verification, however, shows
only small differences in the dose distributions as obtained with brass apertures and
the mMLC. High- dose regions agree, differences are confined to areas below the 50 %
isodose level, which is a direct consequence of the ragged outline of the mMLC shaped
field. This raggedness decreases with depth due to an increase in multiple Coulomb
scattering. When forming outlines with MLCs the conformity is limited by the leaf width.
In transverse direction the input shape will only be reproduced within half a leaf width.
Depending on the target shape it might be beneficial for the dose distributions to close
the leaf pair at the field edge. The consequence of the leaf width on penumbra amounts
to a 1.2 mm increase in transverse direction for the worst-case scenario of very shallow
ranges. In the majority of clinical situations these limitations should not have a clinically
significant impact. Especially in composite dose distributions of multiple beam directions
the penumbral width of a single proton beam becomes less important. It is, however,
important to note that there might be an appreciable worsening in situations with thick
range compensators considering the large airgap. Differences between mMLC and brass
apertures in depth dose characteristics were found to be negligible.
Considering neutron production tungsten is not an optimal material for a proton
beam collimator. Compared to brass our measurements show in increase in neutron
dose of up to a factor of 2 when using the mMLC. In clinical situations (large airgap
for mMLC), however, the in-field neutron dose is actually higher with brass apertures.
Neutron measurements in our beamline furthermore show 10-20 times lower doses than
in our gantry systems. Final collimators have the largest contributions to the neutron
dose to the patient in the gantries and STAR. The proton beam in STAR is scattered to
a 10 cm field diameter and in the Gantry rooms to 25 cm, i.e. a six times larger area
over which protons are stopped close to the patient. STAR also has a larger SAD (4.6 m
versus 2.3 m) and extensive neutron shielding between the scatterers and the patient.
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Hecksel et al [57] have recently reported in detail on the relationship between neutron
dose and field size. Their findings were reproduced analytically by Anferov [79].
Note that our measurements were performed using single pristine peaks; the delivery
of SOBPs increases the number of Monitor Units, and hence the neutron dose increases
(for example, to achieve an SOBP of 8 cm modulation, the number of MU increases
by a factor of 2.2). Another critical factor is the quality factor to be used. We follow
Mesoloras [77] who uses a quality factor of 5.9 according to Monte-Carlo simulations of
Jiang [75]. Close to the aperture edge Wroe [78] measured a quality factor of 2, increasing
to 7 further away from the radiation field. Hence, compared to Wroe, we overestimate
our values at isocenter by about 300% and underestimate the out-of-field values by
about 15%. This emphasizes the difficulties of comparative neutron measurements and
their analysis. References [70] – [78] report on measurements and simulations in various
beamlines.
It is well known that the energy response of Bonner spheres does not allow highly
accurate measurements of neutron fluxes with spectra as they are produced in proton
therapy beamlines. Cascio et al [80] has investigated the energy response of Bonner
Spheres and measured neutron spectra in detail. The upper energy threshold for neutrons
detectable with these detectors was ≈ 100 MeV. Data measured in beam direction
therefore does not include dose from high-energy neutrons present at this position.
Cascio et al furthermore showed that the energy spectrum for off-axis measurements
is shifted towards lower energies than in beam direction. Neutron measurements done
lateral of the central axis are therefore much less influenced by the energy cut-off of the
detector.
At our institution Bonner spheres have for a long time been the standard detector for
neutrons. Although there are deficiencies when using these detectors, it was important
for the experiments performed for this thesis to allow a comparison of the neutron dose in
our gantry beamlines with doses measured in the STAR beamline. This was accomplished
by using a similar experimental setup as previously done at our facility.
Measurements performed by Wroe et al [81] in our beamline using solid state micro-
dosimeters confirmed the large reduction we found in neutron dose in STAR compared
to the gantry beamlines.
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3.1.5 Conclusion
The main dosimetric characteristics of the Radionics mMLC were investigated in com-
parison to custom brass apertures. Lateral penumbra was found to be slightly wider,
depth doses very similar. Field conformation was acceptable. Neutron dose was clearly
increased with the tungsten collimator, but due to beamline properties still lower than
data gathered in other beamlines. Activation of the leaves was not an issue.
The geometric properties and material choice of the mMLC can be optimized further to
improve dosimetric characteristics. But even though the device was specifically designed
for a photon linear accelerator, we conclude that it can be safely and effectively used for
field shaping in our proton beamline.
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3.2 Dosimetry of small Fields
3.2.1 Introduction
The presented measurements were performed using brass apertures rather than the
mini-multileaf collimator introduced in the previous chapter. Brass apertures allowed
the measurement of larger fields, and the collection of data in the two remaining proton
beamline designs available at our institution. The aim of the study was to gather data in
all beamlines for a wide range of setup parameters, and to possibly derive a generalized
formalism for field size correction of the output in proton therapy. In addition, the
presented data set is applied for routine clinical use.
The output factor (i.e. dose per monitor unit) in passively scattered proton therapy
depends on the beam range and modulation. It therefore needs to be determined for each
treatment field, either by measurement or by model. After eight years of experience with
our equipment we now are able to confidently model the output factor in all beamlines,
eliminating the need for daily field calibrations and freeing up valuable resources [82] [30].
Output models were established based on a set of data measured for a large set of ranges
and modulations, using standard conditions for the experimental setup and machine
settings [30]. In particular, the models for all three beamline designs are based on
measurements obtained with a standard aperture size, and no range compensator. This
means the effect of patient specific hardware is neglected - a widely accepted concept in
proton therapy [83]. It is, however, well known that the output for small fields decreases
due to charged particle disequilibrium. It was therefore essential to quantify the effect of
the field size on the output factor to validate dose calculations of our treatment planning
system for small treatment fields. Our treatment planning system uses a pencil beam
algorithm for dose calculation. The loss of fluence on the central axis can be described
applying the pencil beam formalism [84]. Solving the dose integral on the central axis
and normalizing to the open field dose one obtains:
F (r, σtot) = 1− exp(− r
2
2σ2tot(z)
) (3.1)
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with F , the normalized output factor, r the field radius and σ, the standard deviation
of the angular distribution at depth z. The angular distribution is determined by the
virtual source size and the scatter in range compensator and patient:
σtot =
√
σ2source + σ
2
rc + σ
2
patient (3.2)
The presented measurement series assess how accurately our dose calculation algorithm
can predict the observed field size dependence of the output factor. We show the necessity
to correct for the reduction of the output outside of the treatment planning system, and
describe the method currently used at our facility.
3.2.2 Methods
Our beamlines differ significantly in their design. The dedicated intra-cranial stereotactic
beamline (STAR) employs a binary absorber system to spread and degrade the beam.
The two IBA gantry beamlines use a double scattering system, with a combination of
fixed scatterers, range modulator wheels and second scatterers. Our fixed horizontal eye
treatment station uses single scattering and range modulator wheels to create spread-out
Bragg peaks (SOBP). For this work output factors, i.e. dose in cGy per monitor unit
MU, have been obtained in each of the three beamlines, for an extensive set of field sizes
and proton energies. The position of the measurement point (in the following referred to
as POI - point of interest) is the same as the calibration point: on the central axis in
the center of the SOBP high dose region, aligned with isocenter. Doses were calculated
for the STAR beamline, reproducing the experimental setup (i.e. range, modulation,
aperture size, detector position, air gap) in the CMS XiO treatment planning system,
using the dose calculation algorithm as described by Hong et al [84]. The results were
compared to measurements. In the following we briefly describe the properties of the
beamlines and the series of measurements obtained in each.
The fixed stereotactic intra-cranial system (STAR). This system was described
in detail in Chapter 3.1.2. In short, it is a single scattering system with a fixed initial
proton energy and a large source-to-axis distance varying between 400 and 470 cm and a
source size between 2.5 and 3.5 cm. Fields with diameters between 1.2 cm and 10 cm are
treated. The final collimating custom brass aperture is mounted in a narrow aluminum
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Figure 3.10: Sketch of the STAR beamline. A: monitor chamber 1. B: beam profile monitor.
C: Binary Absorber System. D: range verifier. E: beam stop. F: neutron
shielding G: monitor chambers 2 & 3. H: aluminum tubes. I: nozzle. J: cone
with patient specific hardware.
cone. We can choose between two cone sizes, 6 cm and 10 cm diameter. A sketch of the
beamline is depicted in Figure 3.1.2, and for better comparison to the remaining two
systems in a simplified form in Figure 3.10.
Gantry beamlines. Ranges in the gantry beamlines (see Figure 3.11) vary between 4.6
cm and 25 cm, modulations between 1.5 cm and 25 cm. This range interval is sub-divided
into seven treatment options, each characterized by the combination of range modulator
track and second scatterer in use. This gives each option a unique behavior regarding
output as a function of range and modulation. For the treatment of prostate we use an
eighth treatment option for ranges up to 29 cm, but we excluded this option from the
presented measurement series. The maximum and minimum field diameters are 25 cm
and 1.2 cm, respectively. The beamlines source-to-axis distance (SAD ≈ 227 cm) and
virtual source size (2 cm - 4 cm) are range-dependent.
The patient specific hardware is mounted in a heavy cone consisting mainly of brass,
the snout (3.11, item G). Three snout sizes are available, limiting the field diameter to
12 cm, 18 cm or 25 cm. The beam, however, is always scattered to the maximum field
size of 25 cm diameter, independent of the snout size in use. For the treatment of small
fields (≤ 4.5 cm) a brass adapter (HiHat) can be mounted to the 12 cm snout to allow
closer proximity of the aperture to the patient. This adapter aperture reduces the beam
to a diameter of 4.5 cm. A custom aperture is mounted on top of the adapter for final
collimation. A more detailed description of the beamline design can be found in reference
[82].
The eye beamline. The initial proton energy entering this beamline is constant
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Figure 3.11: Sketch of the gantry nozzle. A: fixed scatterers. B: range modulator wheel. C &
E: scanning magnets. D: second scatterer. F: monitor chambers. G: snout. H &
I: patient specific hardware.
Figure 3.12: Sketch of our eye treatment station. A-D: brass cylinders constituting the nozzle.
E: tapered brass snout. F: final field defining aperture. G: modulator wheel. H:
collimator. J: adjustable thickness degrader. K: fixed thickness degrader. L:
collimator. M: x-ray tube. N: ion chambers.
at 160 MeV. The particle energy is degraded by the fixed and variable degrader (Figure
3.12, right: J & K) to ranges in water less or equal to 4 cm. Spread-out Bragg peaks
of up to full modulation are created by a library of modulator wheels. The majority of
treatment fields are no wider than 28 mm in diameter; the minimum field size treated is
10 mm.
In the gantry beamline and in STAR a 1D-translational water phantom is used in
combination with a PTW N31006 pinpoint ionization chamber (active volume 0.015 cm3)
for performing a series of output measurements for a variety of ranges and field sizes.
Alignment of the translational axis with the central axis of the proton fields was achieved
by using the beamline X-ray system with the ion chamber both in the front and the back
of the water phantom. Lateral alignment was optimized by maximizing the measured
output for an 8 mm diameter field, while iteratively translating the water phantom
in both lateral directions. Gantry beamline measurements included one range in each
option 1-7 (5.2-22.4 cm). In STAR we covered five ranges between 5 cm and 18 cm. The
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Figure 3.13: Calculated and measured doses at the center of a 2cm wide SOBP for the STAR
beamline for ranges of 5 cm (left), 12 cm (middle) and 18 cm (right). Measured
curves are normalized to the dose measured at 60 mm aperture diameter-the
standard aperture size for field calibrations. Measurements were obtained with
small (crosses) and large (circles) cone. Calculated values are indicated with a
star symbol.
detector was placed in the center of a 2 cm wide SOBP. The data in the eyeline were
obtained with a diode (active area ≈ 1 mm2), using a pre-absorber system to bring it to
the correct depth. The mount of the device only allows fine-adjustment of the vertical
position of the detector, hence there is small uncertainty in the alignment in horizontal
direction (≤ 1 mm). We measured outputs for 3.2 cm and 2.7 cm ranges.
3.2.3 Results
Measurement versus calculation for the STAR beamline
Figure 3.13 shows a comparison of measured and calculated doses at SOBP center for
ranges of 5, 12 and 18 cm in the STAR beamline. Since our output model is based
on measurements with a field of 60 mm diameter and the 6 cm cone the curves were
normalized to the output obtained at this reference field size.
The choice of normalization point (i.e. field diameter and cone size) is a clinical
one and results in a shift of the curves. Regardless of the choice of reference condition,
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some statements can be made regarding the general shape of our results. Relative to the
largest field diameter the calculation overestimates the dose in the knee region. Beyond
the knee, calculated doses reach a constant value. The measured data level off only for
much larger field sizes for the ranges of 5 cm and 12 cm, and not at all for a range of
18 cm. The general (1 – exp) - shape of the calculated curves does not hold for the
measurements. It is important to note that this behavior cannot be explained by an
error in the source size used for the dose calculation. Even when trying to adjust to fit
the experimental values, our results cannot be described by Equation 3.1 for medium
and deep ranges. (Nor is it advisable to change for this purpose, since that would also
alter the calculated penumbral width.) As we cannot rely on the dose calculation for the
output of small fields we chose to correct for the field size effect outside of our treatment
planning system by applying a correction factor to the modeled output. In order to
explain our observations and possibly improve future dose calculation algorithms the
data set was extended to investigate the effect for the gantry and eye beamlines.
Measured output versus field size for all three beamlines
The results are plotted in Figures 3.14 - 3.16. Since the output levels off to a constant
value only for shallow ranges, one has to choose a normalization point for the curves.
Our choice is the standard calibration field diameter for each beamline (28 mm for the
eye beamline, 60 mm and the small cone for STAR and 120 mm and the 12 cm snout in
the gantry beamline).
The projected source size in STAR is relatively small due to the long SAD. We
Therefore observe less of a field size effect in this beamline (Figure 3.14) than in the
gantry beamline (Figure 3.15). In both systems, however, we measure a further increase
in dose for field sizes for which lateral equilibrium is established, and no more change
expected. This additional effect is more pronounced for increased ranges. In the gantry
beamline, for example, we observe a 4.2 % increase in output between 40 mm and 120
mm field diameter when R = 22.4 cm. For R = 13.6 cm this is only 1.4%, while the
curve flattens out at a field diameter of 70 mm. The effect of the field size on output
is least pronounced in the eye treatment system (Figure 3.16). Due to the small σtot in
shallow proton beams lateral particle disequilibrium only has a significant impact for
fields with diameters less than 8-10mm. There is a further, shallow linear increase of
0.8 - 1.3 % per cm field diameter (range-dependent) beyond the knee, where constant
output is expected. In short, the measurements in the eye treatment system confirmed
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Figure 3.16: Measurement obtained with a diode in the eye beamline. All outputs are
Normalized to the value for a 28 mm diameter aperture.
the observation of increasing output for large field sizes. However, since the magnitude
of the effect is small for clinically applied field sizes (10 mm in diameter) field size effects
for eye treatments were deemed negligible. In clinical practice we do not apply field size
correction factors to the modeled output for the eye beamline. Seeing that these basic
measurements showed the same trend in all beamlines (i.e. change in output for large
fields) additional measurements were performed to explore the nature of the influence of
field size on output.
Effect of snout size, second scatterer, airgap and distance between POI and
distal 90%
Data obtained at the gantry beamline and at STAR showed no dependence on the snout
or cone used (12 cm with HiHat adapter, 12 cm, 18 cm and 25 cm snouts for gantry
nozzle, 6 cm and 10 cm cone for STAR, Figures 3.14 and 3.15 and Table 3.2). This rules
out an impact of scatter off the snout walls. Gantry beamline measurements with an
open field and the 18 and 25 cm snouts showed no further increase in output compared
to the 120 mm diameter fields (Table 3.2). In the gantry system we then measured
the output of a 20 mm diameter field relative to 120 mm field, Ψ∅20/120, to explore the
influence of second scatterer, distance of the point of interest to distal 90% as well as the
airgap. The purpose is to find the magnitude of the impact of those parameters on the
relation of relative output versus field size. The value is a good indicator for this study
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range [cm] aperture diameter [mm] 12 cm 18 cm 25 cm
5.2 20 99.0 99.5 99.6
40 100.0 99.9 100.3
60 100.0 100.1 100.6
180 (open) 99.7
250 (open) 100.3
10.6 20 95.1 94.7 94.8
40 99.1 98.9 99.3
60 100.0 99.9 99.9
180 (open) 100
250 (open) 100.5
10.6 20 78.9 77.6 76.3
40 95.9 96.2 95.9
60 98.1 98.7 98.5
250 (open) 100
Table 3.2: Data for 18 and 25 cm snouts, compared to 12 cm snout. Output in percent,
relative to the values measured with a 120 mm diameter aperture and the 12 cm
snout. The modulation width was 2 cm. The values for 180 mm and 250 mm field
diameter were acquired with no aperture in place.
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range [cm] option 2nd scatterer RM track Ψ∅20/120[%]
5.8 A1 8 3 98.7
5.9 A2 8 6 98.8
11.6 A4 8 7 94.0
11.7 A5 2 5 94.4
19.8 A6 2 7 82.2
19.9 A7 2 8 83.1
Table 3.3: Influence of the second scatterer and range modulator track on field size effect.
Modulation width was 2 cm.
because the output for fields of 20 mm diameter is notably decreased for all measured
ranges.
1. Second scatterer. An impact of the combination of second scatterer would mean
option dependence of the field size effect. The output was measured for two ranges
differing by 1 mm, one at the high end of an option, the other at the low end of the
next higher option, for transitions between option A1(5.8 cm)/A2(5.9 cm), A4(11.6
cm)/A5(11.7 cm) and A6(19.8 cm)/A7(19.9 cm). Airgap and modulation were kept
constant at 8 cm and 2 cm, respectively. The experiments did not find a significant
dependence on the option in use. The values listed in Table 3.3 show a trend of
an increase of ∆(Ψ∅20/120) per mm range with option (column 6), but it remains
smaller than 1 %.
2. Distance of the point of interest to distal 90 %. We positioned the detector
at a constant depth of 10.6 cm, and varied range and modulation such that the
detector was at the calibration depth for the respective SOBP (i.e. at the center
of the high dose region). The airgap was constant at 8 cm. This effect amounts
to ≈ 0.4 % per cm distance between POI and distal 90 %, adding up to ≈ 3 %
difference in between the minimum and maximum modulation measured (2 and
18.8 cm, respectively, Table 3.4).
3. Airgap. For range and modulation of 19 cm and 2 cm, we varied the airgap between
8 cm and 20 cm. Per cm change in airgap we observed 0.6 % change in Ψ∅20/120
(Table 3.5). This amounts to a maximum difference of 6.6% when varying the airgap
from 8 to 20 cm. This difference can be almost entirely attributed to Ψ∅20 (Table
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range [cm] mod [cm] Ψ∅20/120[%]
11.6 2 94.0
13.1 5 95.0
14.1 7 95.7
15.1 9 96.3
16.1 11 96.6
18.1 15 96.6
20.0 18.8 96.9
Table 3.4: Influence of the distance of the point of interest to the distal 90% depth. Relative
output Measured at 10.6 cm depth
airgap Ψ∅20/120 Ψ∅20/120(8cm) [%]
8 82.2 100
14 79.5 96.5
20 75.6 91.5
Table 3.5: Influence of the air gap on field size effect. Relative output measured for a range
and modulation of 19.8 cm and 2 cm. The third column (Ψ∅20/120 relative to
Ψ∅20/120 for 8 cm airgap) shows that the decrease in output is largely caused by a
decrease in Ψ∅20/120.
3.5, column 3). The reference output for the large aperture changes only by 0.8 %
for the 12 cm change in airgap.
3.2.4 Discussion
Extensive measurements in all our beamlines showed that the relation of relative output
and field size cannot be fully explained by charged particle disequilibrium. Additional
measurements in our gantry beamline revealed a weak dependence of the field size effect
on option (≤ 1%, Table 3.3), a notable influence of position of the point of interest with
respect to the distal 90 % (≤ 3 %, Table 3.4) and a strong correlation to the airgap (≤
6.6 %, see Table 3.5).
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Slit scatter as possible explanation
Our results point toward a dose contribution from scattered particles at calibration
depth. Since there is no effect of snout size the snout walls can be excluded as possible
source. The observed very small option-dependence may well be within the measurement
uncertainty, ruling out an influence of the second scatterer and range modulator track.
After eliminating those possibilities, the most likely source of a measurable scattered dose
is the final collimator. This hypothesis is supported by the strong correlation of field size
effect and modulation width as well as airgap. If the inner edge of the collimator acts
as proton source, airgap dependence is explained to first order as inverse-square-effect,
and modulation dependence arises from the increased number of protons needed to
deliver the same dose at point of interest. The importance of collimator scatter was also
pointed out by Titt et al [85], based on Monte Carlo simulations. Van Luijk et al [86] and
Gottschalk [87] have previously described Monte Carlo simulations of collimator-scattered
particles. Kimstrand et al [88] presented a parameterization of collimator scatter for
accurate and fast dose calculation. Sahoo et al [89] presented a method for monitor unit
calculation in passively scattered proton beams, incorporating a correction factor for
the field size. The latter is, however, measured on a field-by-field basis for apertures
smaller than 5x5 cm, and ignored for fields larger than that. We do not consider routine
measurement of field size factors desirable since the data are extremely sensitive to
setup uncertainties. The setup therefore has to be done very carefully and is very time
consuming. Furthermore, depending on range and modulation, even fields larger than
5x5 cm can show 2% reduction in output. For high-accuracy monitor unit calculations
it is necessary to account for the field size effect even for large fields. Recently, our
experimental results were confirmed by Monte Carlo simulations [90].
Clinical Implementation
In our clinical practice field size specific correction factors to the modeled output factors
are applied to STAR and gantry treatment fields. Since the attempt to parameterize
the data did not yield accurate enough results, this correction factor is derived by
interpolation of the obtained data. As parameters for the interpolation we use the
depth of the calibration point (center of the SOBP) and the equivalent diameter of the
treatment field (calculated as the diameter of a circle with the same area as the actual
field).
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This is only an approximation, since the exact field shape is not taken into account.
There might, however, be an appreciable influence of the field shape for larger and more
irregular treatment volumes. This should be investigated further.
The method furthermore does not consider the influence of the position of the point
of interest with respect to the distal 90%. In other words, our correction is based entirely
on the depth of the calibration point, not considering the exact range and modulation
of the field. This is justified by the data presented in section 3.2.3, which showed that
the output of a 20 mm field relative to a 120 mm field changed by only ≤ 3 % when
varying the modulation by 16.8 cm. This change in the relative output with modulation
width will be smaller for larger field sizes. The effect of neglecting a fields range and
modulation – using the depth of the calibration point as parameter to derive the field size
correction – will be small considering that fields that require large modulations require
large apertures as well. To illustrate this we now look at the data for a 20 mm aperture
where we would like to derive the field size correction factor to the output for a range of
13.1 cm and a modulation of 5 cm, reference depth 10.6 cm. In our clinical practice we
would now interpolate between the data presented in Figure 3.15, and as a result use the
factor 94.4%. The exact measurement gives 95.0%, a difference of 0.6%. For small fields
the high dose region becomes increasingly skewed. We therefore use the POI rather than
the range as parameter for the interpolation
The impact of the airgap is neglected in our procedure. The measurements presented
in Figures 3.14 – 3.16 were obtained with an airgap of 8 cm (including the thickness of
the range compensator), corresponding to the average clinical value.
Data depicted in Figure 3.5 show good agreement between measurements obtained
under the same conditions with brass apertures and the mini-multileaf collimator. The
airgap for both collimator types, however, will differ since the bulky MLC cannot be
positioned as close to the patient as the smaller brass apertures. For optimum accuracy
in MLC based IMPT delivery a separate data set should be gathered with this device for
clinically relevant airgaps.
3.2.5 Conclusion
The field size dependence of the output factor cannot be fully explained by loss of fluence
resulting from charged particle disequilibrium. Our data show a further change in output
even for fields large enough for lateral equilibrium. This makes the impact of field size on
78 Experimental Studies
the output a significant factor for precise prediction models even for large treatment fields.
Based on our results it is necessary to incorporate a field specific size correction factor
into the output prediction models of two of our three differently designed beamlines,
not only for small fields. In MLC based IMPT, the monitor unit calculation has to be
corrected for the field size effect on a segment–by–segment basis.
Chapter 4
Conclusions
4.1 Summary of Results
The proton therapy field is rapidly shifting towards pencil beam scanning proton therapy.
Passive scattering beamlines will, however, be part of the proton therapy landscape in
the near and intermediate future as they were designed to be in service for multiple
decades and as, more importantly, they can already provide the highest quality treatment
for most of the patients that are currently being treated with proton therapy. The goal
of our work was to investigate the details of using a multi-leaf collimator in such a
passive-scattered proton beamline. In the introduction of this thesis we formulated four
questions related to the use of an MLC in proton therapy. In this section we provide a
brief summary of how we believe to have answered these questions.
Can IMPT in fixed beamlines offer advantages with respect to conformal
(passively scattered) proton therapy?
The benefit of IMPT in an existing fixed horizontal passive scattering beamline is
the widened range of applications for fixed proton beams with this technique. Dose
distributions achievable for intra-cranial target locations with beam directions constrained
to the coronal plane were qualitatively equal to plans calculated without restriction
on beam angles. In some situations, however, dose to healthy brain may be increased.
Chapter 2.1.
Is it feasible to deliver IMPT with an MLC, considering treatment time
and neutron dose?
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The technical feasibility of MLC based IMPT was examined and neutron dose
estimated. We concluded that IMPT dose distributions can be sequenced into a reasonable
number of segments that technically enables MLC based IMPT. Neutron dose is increased
but is limited to an acceptable level with an optimized beamline design. Chapter 2.2.
What are the properties of a multileaf collimator in a proton beam?
The quality of proton dose distributions shaped by multileaf collimators differs from
the commonly applied custom milled apertures. Properties of one specific MLC optimized
for photon therapy were measured and compared to custom brass apertures. Penumbras
were found to be slightly increased due to a combination of the effect of the ragged
aperture outline, and the increased air gap. The influence of the airgap is beamline
specific since it depends strongly on source-to-axis distance. Chapter 3.1. Further
improvement may be achievable with a proton therapy – optimized MLC.
What is the relationship between peak dose and MLC field size?
The correlation between proton output factor and field size was described in prepara-
tion of the IMPT delivery. A large data set was gathered to supply the accuracy needed
for the delivery of many small fields that together will determine the 3D intensity and
dose distribution. Chapter 3.2.
4.2 Limitations of this work
Our segmentation study (Chapter 2.2) indicates that an IMPT intensity-distribution can
be broken down into a deliverable number of intensity-segments. Our analysis does not
address how to reproduce these intensity-segments by means of MLC leaf settings. Using
the current setup for treatment planning and segmentation those leaf shapes would have
to be set such that they produce a dose distribution similar enough to the one created
with a scanned beam for the segmented intensity maps.
Dosimetric properties were investigated for just a single multileaf collimator, having
a small leaf width. The mini-multileaf collimator used was originally designed to be
used for stereotactic photon radiotherapy. We expect that MLCs that will be applied
in clinical routine in proton therapy will have different design properties. For example,
the effect of the jagged field outline on penumbra and conformality will be worse for
wider leaves. Activation of the MLC device due to quasi-continuous exposure as part of
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routine clinical operation may be a larger issue for larger devices. It should be stressed
that although our results are specific to the device investigated, the methodology and
the set of tests described remain valid.
In MLC based IMPT many segments delivered will be off-axis, while the data we
presented in Chapter 3.2 was limited to field shapes that contain the central axis. Use of
off-axis segments has consequences for the dose distributions. The main consequence is
an increased penumbra on the medial side of the segment as, for example, indicated by
Slopsema et al [91]. This effect should be measured and depending on its magnitude it
will have to be included in the dose calculation. The magnitude of the effect depends on
beamline source-to-axis distance, airgap, collimator thickness and distance to the field
edge from the central axis.
Our studies were part of a project of extending the capabilities of our own fixed
horizontal beam line. This beam line and its patient positioner have been specifically
designed to treat intra-cranial tumors. The methodologies and results presented regarding
neutron dose in Chapter 2.2.3 and Chapter 3.1.3, are also of value for the use of MLCs
in the treatment of other tumor sites such as those located in the thorax and abdomen
region. Regarding our segmentation study (Chapter 2.2), however, we believe it not to be
directly applicable for such targets as they tend to have a much larger volume. They may
therefore require many more segments than needed for the accurate treatment of smaller
intra-cranial tumors, unless special measures are taken. Based on our segmentation study
alone it can not be concluded that MLC-based IMPT is feasible for any tumor location.
4.3 Discussion
Multileaf collimators offer a range of applications to proton therapy. The most basic form
of utilization is in 3D conformal proton therapy. This eliminates the need for custom
milled apertures. It thereby reduces the cost of material and labor to fabricate these
apertures and, more importantly, it simplifies treatment planning and treatment logistics.
The implementation of a layer stacking method with leaf shape variable between range
layers constitutes a more complex use of an MLC and can provide increased proximal
conformality of proton dose distributions. The most complex method of dose delivery
with an MLC is intensity modulated proton therapy.
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One of the research topics in photon radiotherapy for the past few years has been
direct aperture optimization (DAO, e.g. [92] and [93]). The benefits of DAO are that
allows the user to directly control of the number of segments in a treatment, and that
the optimized dose distribution is an accurate representation of what will be delivered.
Without DAO the leaf-sequencing step that is necessary to translate an optimized
intensity distribution into deliverable segments typically will lead to a degradation of
the optimized dose distribution. Both these benefits of DAO are very valuable also for
the clinical implementation of MLC-based IMPT. With optimization software based on
DAO, the number of segments, and therefore the neutron dose to the patient, can be
directly controlled. Ideally, an optimizer for MLC-based IMPT would, or could, also take
into account the possibility of using small SOBPs rather than single pristine peaks for
optimization (see Chapter 2.2).
In recent years emphasis in radiotherapy development has been placed on the ap-
plication of adaptive radiotherapy. Proton therapy with custom made hardware makes
adaptation of the treatment a logistical challenge and is currently applied in only very
limited form and for few patients. Multileaf collimators add flexibility and open new
possibilities to proton therapy in this regard.
Moving targets remain a major challenge for radiotherapy in general, and even more
so for proton therapy. Multiple proton therapy institutes are working on strategies to
safely treat moving targets with scanned proton beams. Fast rescanning of the target
volume (e.g. [94] [95]), gating (e.g. [95] [96] [97]) and tracking (e.g. for photon therapy
[98], and for particles [95] [99] [100]) are some of the strategies under development. If
moving targets are to be treated with MLC based IMPT these strategies will have to
be adapted to be feasible for MLC delivery. MLC based IMPT for moving targets will
likely be too slow to allow multiple deliveries a practical way to reduce the effects of
interplay similar to rescanning with pencil beam delivery. Depending on the time needed
to deliver the treatment, gating may be too large a burden for the patient. Although
beams eye view tumor tracking will be possible with an MLC, a major open question is
how to address motion-induced density variations. Although it is possible to vary the
energy for a proton-segment, the required energy variation may be different for various
regions of the segment. Perhaps the treatment of moving tumors with MLC-based IMPT
should be limited to those patients having only restricted target motion, and delivery
techniques that inhibit or minimize target motion, such as breath-hold.
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4.4 Future Directions
The multileaf collimator studied here was originally designed for photon therapy. The
design can be optimized for proton therapy, with for example thinner leaves, straight
edges or a material minimizing neutron production. The latter is not trivial considering
mechanics of leaves moving closely next to each other.
Currently, using the MLC entails manually mounting it to the treatment head. Leaf
shapes have to be manually loaded and set one by one. For applications in treatments
the device has to be fully integrated into the treatment control system. This includes
the pure mechanics, such as designing a hoisting mechanism. It includes software and
electronics to automatically load and set leaf shapes. And it includes various interlocks
to provide the necessary, redundant, safety features.
The treatment planning system has to accommodate dose calculation for collimation
with an MLC. A commissioning procedure for the TPS has to be designed and executed.
A mechanism has to be invented to produce data files that define a sequence of leaf
shapes and proton energies for the treatment control system; as well as a redundant
checking system on the integrity and validity of these files.
For quality assurance of MLC based IMPT dose distributions patient specific three-
dimensional dosimetry is necessary. Unlike for IMRT there are no commercial solutions
on the market as of yet. Currently, facilities employ ion chamber arrays to measure
two-dimensional profiles at different depths. The design and implementation of a QA
program will require additional resources.
4.5 Conclusion
Our work addressed a number of questions regarding the use of MLCs in passive-scattered
proton beamlines. Dosimetric characteristics have been shown to be clinically acceptable
and can be further improved by the design of a dedicated proton MLC. Although MLCs
in proton therapy will not allow the same flexibility as pencil beam scanning, their use
increases workflow efficiency and will enhance the capabilities of existing and future
passive-scattered proton beamlines.
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